CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
1
Biogen MA Inc.
250 Binney Street
Cambridge, MA 02142
United States
PROTOCOL NUMBER: 101SK202/[STUDY_ID_REMOVED]Biogen Idec Research Limited
Innovation House
70 Norden Road
Maidenhead Berkshire
SL6 4AY
United Kingdom
PHASE OF DEVELOPMENT: 2
PROTOCOL TITLE: A Multicenter, Double -Blind, Placebo- Controlled, Randomized, 
Parallel -Group ,Dose -Ranging Study  to Evaluate the Safet y and Efficacy of I ntravenous 
Natalizumab (BG00002) in Acute Ischemic Stroke
EUDRA CT NO: 2015-004783-11
DATE: 03 M ay2017
Version 3.0
FINAL
Supersedes previous Version 2.0 dated 15 Dec ember 2016.
Protocol 101SK202 Versio n 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3TABLE OF CONTENTS
SPONSOR SI GNATURE PA GE................................ ................................ ................................ ....2
1. SPONSOR I NFORMATION ................................ ................................ ....................... 8
2. LIST OF ABBREVIATION S................................ ................................ ....................... 9
3. SYNOPSI S ................................ ................................ ................................ ................. 11
4. STUDY SCHEMATI C AND SCHEDULE OF ACTI VITIES FOR STUDY 
101SK202 ................................ ................................ ................................ ................... 15
4.1. Study  Schematic ................................ ................................ ................................ ......... 15
4.2. Schedule of Activities ................................ ................................ ................................ .16
5. INTRODUCTION ................................ ................................ ................................ ......18
5.1. Overview of Acute Ischemic Stroke ................................ ................................ ........... 18
5.2. Current Therapies for Acute I schemic Stroke ................................ ............................ 19
5.3. Profile of Previous Experience With Natalizumab.....................................................19
5.3.1. Nonclinical Experience ................................ ................................ ............................... 19
5.3.2. Clinical Experience................................ ................................ ................................ .....19
5.4. Study  Rationale ................................ ................................ ................................ ........... 20
5.4.1. Role of Inflammation in Stroke ................................ ................................ .................. 20
5.4.2. Preclinical Rationale ................................ ................................ ................................ ...20
5.4.3. Clinical Rationale ................................ ................................ ................................ .......21
5.5. Rationale for the Treatment Windo w of ≤24 Hours From LKN ................................ 21
5.6. Rationale for Dosing Regimen ................................ ................................ ................... 22
5.6.1. Rationale for Comparator/Reference Product or Placebo ................................ .......... 22
6. STUDY OBJECTIVES AND ENDPOINTS ................................ .............................. 23
6.1. Primary  Objective and Endpoint ................................ ................................ ................ 23
6.2. Secondary  Objectives and Endpoints ................................ ................................ ......... 23
6.3. Exploratory  Objectives and Endpoints ................................ ................................ .......23
7. STUDY DESIGN ................................ ................................ ................................ .......25
7.1. Study  Overview ................................ ................................ ................................ .......... 25
7.2. Overall Study  Duration and Follow -Up................................ ................................ .....25
7.2.1. Screening ................................ ................................ ................................ .................... 25
7.2.2. Treatment ................................ ................................ ................................ .................... 25
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
47.2.3. Follow -Up................................ ................................ ................................ ................... 25
7.3. Study  Stopping Rules ................................ ................................ ................................ .26
7.4. End of Study ................................ ................................ ................................ ............... 26
8. SELECTION OF SUBJECTS ....................................................................................27
8.1. Inclusion Criteria ........................................................................................................27
8.2. Exclusion Criteria ................................ ................................ ................................ .......28
9. ENROLLMENT, REGISTRA TION, AND RANDOMIZAT ION ............................ 30
9.1. Screenin g and Enrollment ................................ ................................ ........................... 30
9.2. Randomization and Registration of Subjects ................................ .............................. 30
9.3. Blinding Procedures ................................ ................................ ................................ ....30
10. DISCONTINUATION OF S TUDY TREATMENT AND/O R 
WITHDRAWA L OF SUBJECTS FROM THE STUDY ................................ ........... 31
10.1. Discontinuation of Study Treatment ................................ ................................ ........... 31
10.2. Withdrawal of Subjects From Study...........................................................................31
11. STUDY TREATMENT USE ................................ ................................ ..................... 33
11.1. Regimen ................................ ................................ ................................ ...................... 33
11.2. Modification of Dose and/or Treatment Schedule ................................ ...................... 33
11.3. Precautions ................................ ................................ ................................ .................. 33
11.4. Compliance ................................ ................................ ................................ ................. 33
11.5. Concomitant Therap y and Procedures ................................ ................................ ........ 33
11.5.1. Concomitant Therap y .................................................................................................33
11.5.1.1. Allowed Concomitant Therap y................................ ................................ ................... 33
11.5.1.2. Disallow ed Concomitant Therap y ................................ ................................ .............. 34
11.5.2. Concomitant Procedures ................................ ................................ ............................. 34
11.6. Continuation of Treatment ................................ ................................ .......................... 34
12. STUDY TREATMENT MANA GEMENT ................................ ................................ 35
12.1. Natalizumab ................................ ................................ ................................ ................ 35
12.1.1. Natalizumab Preparation ................................ ................................ ............................ 35
12.1.2. Natalizumab Storage ................................ ................................ ................................ ...35
12.1.3. Natalizumab Handling and Disposal ................................ ................................ .......... 36
12.1.4. Natalizumab Accountability ................................ ................................ ....................... 36
12.2. Placebo ................................ ................................ ................................ ........................ 36
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
513. EFFI CACY, PHARMACOKI NETIC, AND PHARMACOD YNAMIC 
ASSESSMENTS ................................ ................................ ................................ ......... 37
13.1. Clinic al Efficacy  Assessments ................................ ................................ .................... 37
13.2. Pharmacokinetic Assessments ................................ ................................ .................... 39
13.3. Pharmacod ynamic Assessments ................................ ................................ ................. 39
14. SAFETY ASSESSMENTS ................................ ................................ ........................ 40
14.1. Clinical Safety  Assessments ................................ ................................ ....................... 40
14.2. Laboratory  Safet y Assessments ................................ ................................ .................. 40
15. SAFETY DEFINITIONS, RECORDI NG, REPORTI NG, AND 
RESPONSIBILIT IES................................ ................................ ................................ .41
15.1. Definitions ................................ ................................ ................................ .................. 41
15.1.1. Serious Pretreatment Event ................................ ................................ ......................... 41
15.1.2. Adverse Event ................................ ................................ ................................ ............. 41
15.1.3. Serious Adverse Event ................................ ................................ ................................ 41
15.1.4. Prescheduled or Elective Procedures or Routinely  Scheduled Treatments ................ 42
15.2. Safety  Classifications ................................ ................................ ................................ ..42
15.2.1. Investigator Assessment of Events ................................ ................................ ............. 42
15.2.2. Relationship of Events to Study  Treatment ................................ ................................ 43
15.2.3. Severity  of Events ................................ ................................ ................................ .......43
15.2.4. Expectedness of Events ................................ ................................ .............................. 43
15.3. Monitoring and Recording Events ................................ ................................ .............. 44
15.3.1. Adverse Events ................................ ................................ ................................ ........... 44
15.3.2. Serious Adverse Events ................................ ................................ .............................. 44
15.3.3. Immediate Reporting of Serious Adverse Events................................ ....................... 44
15.3.3.1. Deaths ................................ ................................ ................................ ......................... 45
15.3.4. Suspected Unexpected Serious Adverse Reactions................................ .................... 45
15.4. Procedures for Handling Special Situations ................................ ............................... 45
15.4.1. Pregnancy ................................ ................................ ................................ ................... 45
15.4.2. Overdose ................................ ................................ ................................ ..................... 45
15.4.3. Medical Emergency ................................ ................................ ................................ ....46
15.4.3.1. Unblinding for Medical Emergency ................................ ................................ ........... 46
15.5. Contraception Require ments ................................ ................................ ...................... 46
15.6. Safety  Responsibilities................................................................................................47
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
615.6.1. The Investigator ................................ ................................ ................................ .......... 47
15.6.2. Biogen ................................ ................................ ................................ ......................... 48
16. STATI STICAL METHODS AND DETERMINATION OF SAMPL E SIZE...........49
16.1. Efficacy ................................ ................................ ................................ ....................... 49
16.1.1. Analy sis Population ................................ ................................ ................................ ....49
16.1.2. Methods of Anal ysis................................ ................................ ................................ ...49
16.1.2.1. Analysis of the Primary  Endpoint ................................ ................................ ............... 49
16.1.2.2. Analy sis of the Secondary  Endpoints ................................ ................................ ......... 49
16.1.2.3. Additional/Exploratory  Endpoints Analy sis................................ ............................... 51
16.2. Pharmacoki netics ................................ ................................ ................................ ........ 51
16.2.1. Analy sis Population ................................ ................................ ................................ ....51
16.2.2. Methods of Anal ysis................................ ................................ ................................ ...51
16.3. Pharmacod ynamics ................................ ................................ ................................ .....52
16.3.1. Analy sis Popul ation ................................ ................................ ................................ ....52
16.3.2. Methods of Anal ysis................................ ................................ ................................ ...52
16.4. Safety ................................ ................................ ................................ .......................... 52
16.4.1. Analy sis Population ................................ ................................ ................................ ....52
16.4.2. Methods of Anal ysis................................ ................................ ................................ ...52
16.4.2.1. Adverse Events ................................ ................................ ................................ ........... 53
16.4.2.2. Clinical L aboratory  Results ................................ ................................ ........................ 53
16.4.2.3. Vital Signs ................................ ................................ ................................ .................. 53
16.5. Interim Anal yses................................ ................................ ................................ ......... 53
16.6. Sample Size Considerations ................................ ................................ ....................... 53
17. ETHI CAL  REQUIREMENTS ................................ ................................ ................... 54
17.1. Declaration of Helsinki ................................ ................................ ............................... 54
17.2. Ethics Committee ................................ ................................ ................................ ........ 54
17.3. Subject I nformation and Consent ................................ ................................ ............... 54
17.4. Subject Data Protection ................................ ................................ .............................. 55
17.5. Compensation for Injury ................................ ................................ ............................. 55
17.6. Confli ct of I nterest ................................ ................................ ................................ ......55
17.7. Registration of Stud y and Disclosure of Study Results ................................ .............. 55
18. ADMINISTRATIVE PROCE DURES ................................ ................................ .......56
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
718.1. Study  Site Initiation ................................ ................................ ................................ ....56
18.2. Quality  Assurance ................................ ................................ ................................ .......56
18.3. Monitoring of the Stud y................................ ................................ .............................. 56
18.4. Study  Funding ................................ ................................ ................................ ............. 56
18.5. Publications.................................................................................................................56
19. FURTHER REQUIREMENTS AND GENERAL INFORMAT ION........................ 57
19.1. External Contract Organizations................................ ................................ ................. 57
19.1.1. Contract Research Organization ................................ ................................ ................. 57
19.1.2. I nteractive Response Technology ................................ ................................ ............... 57
19.1.3. Remote Data Capture ................................ ................................ ................................ ..57
19.1.4. Central Laboratories for Laboratory  Assessments ................................ ..................... 57
19.1.5. Central Facility for O ther Assessments ................................ ................................ ......57
19.2. Study  Committees ................................ ................................ ................................ .......57
19.2.1. Advisory Committee ................................ ................................ ................................ ...57
19.2.2. Independent Data Safet y Monitoring Committee ................................ ....................... 58
19.3. Changes to Final Study  Protocol ................................ ................................ ................ 58
19.4. Ethics Committee Notification of Study  Completion or Termination........................58
19.5. Retention of Study  Data ................................ ................................ .............................. 58
19.6. Study  Report Signatory ................................ ................................ ............................... 59
20. REFERENCES ................................ ................................ ................................ ........... 60
21. SIGNED AGREEMENT OF THE STUDY PROTOCOL ................................ ......... 62
LIST OF TABLES
Table 1: Schedule of Activities for Study  101SK202 ................................ ............................... 16
LIST OF FIGURES
Figure 1: Study  Design ................................ ................................ ................................ ............... 15
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
81. SPONSOR INFORMATION
Biogen MA Inc.
250 Binney  Street
Cambridge, MA 02142
United StatesBiogen Idec Resear ch Limited
Innovation House
70 Norden Road
Maidenhead, Berkshire 
SL64AY
United Kingdom
For urgent medical issues in which the study ’s Medical Monitor should be contacted, please refer 
to the Study  Reference Ma nual’sOfficial Study  Contact L ist for comp lete contact information.
Biogen may  transfer any  or all of its study -related responsibilities to a contract research 
organization (CRO) and other third parties; however, Biogen retains overall accountability for 
these activities.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
92. LIST OF ABBREVIATION S
AE adverse event
AUC area under the serum concentration versus time curve
AUC 0-120 area under the serum concentration versus time curve from dosing (time=0) 
to 120 hours after dosing
AUC 0-2160 area under the serum concentration versus time curve from dosin g (time=0) 
to 2160 hours after dosing
AUC 0-672 area under the serum concentration versus time curve from dosing (time=0) 
to 672 hours after dosing
AUC 0-last area under the serum concentration versus time curve, from dosing (time=0) 
to last measurable con centration
BDI-2 Beck Depression Inventory 2
BI Barthel Index
CD Crohn’s disease
CI confidence interval
Cmax maxim um serum concentration
CRO contract research organization
CT computed tomography
DAMPs damage associated molecular patterns
DHA Direc tions for Handling and Administration
DSMC Data Safety Monitoring Committee
EC ethics committee
eCRF electronic case report form
FIM Functional Independence Measure
FSS Fatigue Severity Scale
GCP Good Clinical Practice
HRU health resource utilizatio n
ICF Informed Consent Form
ICH International Council on Harmonisation
IRB institutional review board
IRT interactive response technology
IV intravenous
IXRS Interactive Voice/Web Response System
JCV John Cunningham virus
LKN last known normal
MoC A Montreal Cognitive Assessment
MRI magnetic resonance imaging
mRS modified Rankin Scale
MS multiple sclerosis
NIHSS National Institute of Health Stroke Scale
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
10OR odds ratio
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PML progressive multifocal leuk oencephalopathy
RDC remote data capture
rtPA recombinant tissue plasminogen activator
SAE serious adverse event
SAP statistical analysis plan
SDMT Symbol -Digits Modalities Test
SE standard error
SIS-16 Stroke Impact Scale -16
SUSAR suspected unexpec ted serious adverse reaction
t½ half-life
tlast time of last measurable concentration
tmax time to C max
tPA tissue plasminogen activator
US United States
VCAM -1 vascular cell adhesion molecule -1
VLA -4 α4β1 integrin, also known as very late antigen -4
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
113. SYNOPSIS
Protocol Number: 101SK202
Protocol Title: A Multicenter, Double -Blind, Placebo- Controlled, 
Randomized, Parallel -Group, Dose -Ranging Study  to 
Evaluate the Safet y and Efficacy of Intravenous 
Natalizumab (BG00002) in Acute Ischemic Stroke
Version Number 3.0
Name of Stud y Treatment: BG00002 (natalizumab; Ty sabri)
Study  Indication: Acute Ischemic Stroke
Study  Rationale Stroke is a leading cause of mortality  and serious long -term 
disability .  There is a substantial unmet medical need for 
new thera pies that can improve outcomes in acute stroke.
Experimental and pathologic data suggest that peri -infarct 
inflammation contributes to secondary  injury  after brain 
ischemia and that blocking inflammation reduces neuronal 
injury  and improves clinical outcomes.
Natalizumab is a humanized monoclonal antibody approved 
for the treatment of both relapsing multiple sclerosis and 
Crohn’s disease that blocks α4β1 -or α4β7- integrin -
mediated adhesion of leukocy tes to vascular endothelial 
cells and inhibits the transmigrat ion of leukocy tes into 
inflamed parench ymal tissue.
In Stud y 101SK201 (ACTION), while treatment with 
natalizumab did not reduce magnetic resonance 
imaging -defined infarct volume, there was evidence that it 
resulted in clinical benefit in patients with acut e ischemic 
stroke, and no safet y concerns were identified. 
This study  (101SK202) will assess dose response and 
overall safety  and efficacy  of natalizumab in subjects with 
acute ischemic stroke.   Time dependency  of treatment 
effects will also be assessed t hrough a treatment window of 
up to 24 hours from last known normal (LKN) .
Phase of Development: 2
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
12Study  Objectives and 
Endpoints:The primary  objective of the study  is to assess the effects of 
natalizumab versus placebo in acute ischemic stroke on 
clinic al measures of independence and activities of daily  
life.
The primary  efficacy  endpoint is a composite global 
measure of functional disability  based on a score of 0 or 1 
on the modified Rankin scale (mRS) and a score of ≥95 on 
the Barthel Index (BI) at Day  90 [Tilley  1996] . 
The secondary  objective of the study  is to explore dose and 
exposure response , time dependency  of the treatment effect,
andthe clinical treatment effects of natalizumab versus 
placebo in acute ischemic stroke on the following measures 
of independence, activities of dail y living, neurologic 
function, quality  of life, and cognition and safet y and 
tolerability .
The secondary  endpoints are:
mRS score a t Day  90
BIscore at Day  90
Stroke I mpact Scale -16score at Day 90
Montreal Cognitive Assessment score at Day  90
Safety  (incidence and proportion of adverse 
events and serious adverse events)
National Institutes of Health Stroke Scale 
(NIHSS) score at Day 90
The exploratory  objective of this study  isto evaluate the 
effect of natalizumab on measures of function, cognition, 
fatigue, depression, quality  of life, and 
pharmacokinetic/pharmacody namic relationships over time.
The exploratory  endpoints are:
Functi onal Independence Measure score at 
Day 90
Symbol -Digits Modalities Test score at Day  90
Fatigue Severity  Scale score at Day  90
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
13Beck Depression Inventory  2 score
Serum concentrations of natalizumab at selected 
times after dosing
Blood biomarkers of natalizumab
Subject direct resource use (assessed using a 
health resource utilization questionnaire)
EuroQoL EQ -5D-3L (questionnaire)
Study  Design: This is a Phase 2 multicenter, double -blind, 
placebo- controlled, randomized, 3- arm,dose-ranging stud y. 
Study  Location: Approximately  67sites in the United States and Europe are 
planned.
Number of Planned Subjects: Approximately  270 subjects are expected to be enrolled.  Of 
these, no more than 90 subjects will be treated between >9 
and≤24 hours from LKN .
Study  Population: This study  will be conducted in subjects aged 18 to 80 y ears 
with acute ischemic stroke defined b y LKN at ≤24 hours
prior to study  treatment initiation .
Detailed criteria are described in Section 8.
Treatment Groups : All subjects will receive 1 dose of study  treatment at 
Screening according to their randomization in a 1:1:1 ratio 
to 1 of the following 3 treatment groups:
Natalizumab 600 mg intravenous ( IV)in 
approximately  90subjects
Natalizumab 300 mg IV in approxi mately  
90subjects
Placebo IV in approximately  90subjects
Randomization will occur separatel y within each treatment 
window.  Fo r subjects in the ≤9 hour treatment window, 
randomization will be stratified by  baseline NIHSS category  
(NIHSS scores from 5 to 15 or 16 to 23), tissue plasminogen 
activator (tPA) use (y es or no), and region; for subjects in 
the >9 to ≤24 hour window, rand omization will be stratified 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used , disclosed, or published w ithout the written consent of 
Biogen MA Inc.
14by tPA use (y es or no) and region.
Duration of Treatment and 
Follow -up:Subjects will participate in this study  for approximately  
90days.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
154. STUDY SCHEMATIC AND SCHEDULE OF ACTIVITIES FOR 
STUDY 101SK202
4.1. Study Schematic
The study  design is display ed in Figure 1.
Figure 1: Study Design
LKN = last known normal; NA = natalizumab; R = randomization .
Note: PK/PD/biomarkers are performed within 1 hour after the end of the infusion.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
164.2. Schedule of Activities
Table 1: Schedule of Activities for Study 101SK202
Tests and Assessments Screening10 Hours2
(Day 1)Within 1 Hour 
After End of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination4
±5 Days
Informed consent X
Confirm eligibility X
Demographics and medical 
history5X
Physical and neurological 
examinationX X X X X
Vital signs6X X X X X X X
Height (if available) and weight X (anytime from Screening to Day 5 Visit)
Urine pregnancy test7X
Hematology and blood 
chemistryX X X X X X
Serum biomarkers X X X X X X
PD sampling X X X X X X X
PK sampling X X X X X X X
Blood sample for 
anti-natalizumab antibodiesX X X
NIHSS X X2X X X X
mRS X8X X
BI X X X
SIS-16 X9X X
MoCA X X X
Functional I ndependence 
MeasureX X
SDMT X X X
Fatigue Severity Scale X9X X
Beck Depression I nventory 2 X9X X
HRU questionnaire X X X
EQ-5D-3L X X X
Study treatment administration10X
Stroke subtype classification11X
SAE reporting Record as per Section 15.3.2of the protocol
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MA Inc.
17Tests and Assessments Screening10 Hours2
(Day 1)Within 1 Hour 
After End of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination4
±5 Days
AE reporting Record as per Section 15.3.1 of the protocol
Concomitant medications Record a s per Section 11.5 of the protocol
Concomitant procedures Record as per Section 11.5 of the protocol
AE = adverse event; BI = Barthel Index; BDI-2= Beck Depression Inventory 2; CT= computed tomography; ECG = electrocardiogram; FIM = Functional Independe nce Measure ; 
FSS =Fatigue Severity Scale ; HRU = health resource utilization; LKN = last known normal; MoCA = Montreal Cognitive Assessment; MRI = magnetic resonance im aging; 
mRS = modified Rankin Scale; NIHSS = National Institute of Health Stroke Scale; P D =pharmacodynamic; PK =pharmacokinetic; SAE = serious adverse event; SDMT = 
Symbol -Digits Modalities Test; SIS -16 = Stroke Impact Scale -16.
Note:  All timepoints , except “w ithin 1 hour after the end of the infusion” ,are relative to start of study treat ment administration .
1All Screening assessments must be performed prior to infusion.  Screening assessments that are performed as standard of care do not need to be repeated for the study, provided 
that Biogen has access to the information and data are re corded in subject’s case report form.  Data collected for the Screening assessments will be used for patient baseline 
analysis in this study.  The ECG and CT or MRI assessments results should already be available at Screening ( as they are performed as part of the standard of care), and a copy 
of the images andreport should be filed with the subject ’sstudy records .
2The 0 Hours vital signs assessments are to be performed within 15 minutes prior to study treatment administration.  If the Screening NIHSS is performed more than 1 hour 
prior to study treatment adminis tration, it must be repeated during the visit at 0 Hours before study treatment administration .
3Day 5 assessments are to occur on Day 5 or earlier if discharged, but must occur prior to discharg e.
4The subject will be asked to complete the Day 30 andDay 90 Follow -UporEarly Termination assessments in person (see Section 7.2.3 and Section 10.2).  If the subject is 
unable to return to the study center to complete the Day 30 orDay 90 (Follow -up or Early Termination )assessments in person, safety information will be collected by 
telephone or remotely, as local regulations allow and pending medical monitor approval, and will include the collection of AEs, SAEs, FIM, mRS, BI, BDI- 2, SIS -16, EQ -5D-
3L, physical/neurological exam ination , vital signs, hematology/blood chemistry, serum biomarkers, PD sampling, PK sampling, anti -natalizumab antibodies, NIHSS, MoCA, 
SDMT, FSS, HRU, and concomitant medications.
5Medical history should include an assessment of prior substance abuse.
6Vital signs collected at each of the specified timepoints include temperature, blood pressure, pulse or heart rate, and respi ratory rate.  Vital signs collected as part of the 
subject’s standard of care and that fall within 30 m inutes of a study visit do not need to be repeated for the study, provided that Biogen has access to the information and data 
are recorded in the subject’s case report form.
7Required only for women of childbearing potential.  If a serum beta human chorio nic gonadotropin test was performed as part of the subject’s standard of care, the results will 
be accepted in lieu of the urine pregnancy test.
8An mRS assessment will be done on Day 5, or earlier if discharged.
9Per instructions on the SIS -16, BDI -2,and FSS form s, the subject or proxy should provide responses as it applies to the prior 2 week period.  When completing the SIS -16 
BDI-2, and FSS assessments during the Day 5 Visit, the subject or proxy should consider only the time period starting between the initial stroke (LKN) and the Day 5 Visit.
10The subject must be observed for 1 hour after completion of infusion.
11The stroke etiology will be assessed based on the subject’s standard of care and diagnostic testing.  This should be complete d at Day 5 or earlier if discharged, but if results are 
incomplete, it may be completed at Day 30.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
185. INTRODUCTION
Natalizumab is a recombinant humanized monoclonal antibody  approved in the United States 
(US), European Union, and multiple other countries for the trea tment of relapsing multiple 
sclerosis (MS).  It is also approved for the treatment of Crohn’s disease (CD) in the US.  
Natalizu mab is produced in a murine my eloma cell line (NS/0) and binds to the α4 subunit of 
human integrin, which is expressed at high levels on all circulating human leukocy tes except 
polymorphonuclear leukocy tes.
Natalizumab binding blocks the interaction of α4β 1 integrin (also known as very  late antigen -4 
[VLA-4]) on leukocy tes with its counter receptor, vascular cell adhesion molecule -1 (VCAM -1) 
and fibronectin, located on endothelial cells.  Likewise, natalizumab blocks the interaction of 
α4β7 integrin express ed on leukocy tes with mucosal addressin cell adhesion molecule -1.  
Disruption of these cell adhesion molecule interactions prevents trafficking of mononuclear 
leukocy tes across the endothelium and into parenchy mal tissue.  This is believed to be the basis 
of its efficacy  in MS and CD, and in clinical studies, natalizumab has demonstrated reduction in 
MS relapse rates b y approximately  70%.  
Experimental and pathologic data suggest that peri -infarct inflammation in patients with 
ischemic stroke contributes t o secondary  injury  after brain ischemia, and blocking inflammation 
reduces the volume of brain infarction and improves clinical outcomes.  The Phase 2a 
Study 101SK201 demonstrated that although natalizumab did not reduce infarct volume, it was 
associated w ith improved clinical outcomes, and no safet y risks were observed.  The observed 
clinical benefits warranted further investigation. 
5.1. Overview of Acute Ischemic Stroke
Stroke occurs when there is an interruption of blood flow to the brain, causing death of neural 
tissue and focal neurological deficits.  The signs and sy mptoms vary  with the location and extent 
of the stroke.  There are nearl y 800,000 strokes of all ty pes per y ear in the US, of which ischemic 
stroke accounts for approximately  80% [Roger 2011 ].  In Europe, the estimated annual incidence 
of stroke is over 1.1 million, with a similar percentage of these (approximately  80%) being 
ischemic strokes [Heuschmann 2009 ; Truelsen 2006] .
Guidelines for the evaluation and treatment of acute stroke patients focu s on reperfusion 
therapies and controlling factors that may exacerbate stroke or complicate the clinical course.  
The diagnosis of acute ischemic stroke is made through a combination of a history  and ph ysical 
examination that is consistent with focal ische mia and a resulting neurologic deficit.  Brain 
imaging, obtained through either computed tomograph y (CT) or magnetic resonance imaging 
(MRI), is used to exclude hemorrhage and other focal pathologies and document earl y signs of 
ischemia. 
Regardless of the mechanism of ischemia, inflammation is thought to contribute to the 
progression of brain injury.  Inflammation was long considered to be merely a reaction to 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
19damaged brain tissue, but recent evidence suggests that inflammation is a key part of ischemic 
injury that stems from both responses in the vasculature and the release of damage associated 
molecular patterns (DAMPs) from ischemic brain tissue [Shichita 2012] .  
5.2. Current Therapies for Acute Ischemic Stroke 
Recombinant tissue plasminogen activator (rtPA) is the only  approved pharmacological therap y 
for acut e ischemic stroke. It is approved for use within 3 hours of stroke onset in the US and 
within 4.5 hours in many European countries. Current American Heart Association guidelines 
also suggest use up to 4.5 hours after stroke onset, although treatment effe cts diminish over time 
and risk of hemorrhage increases [Jauch 2013] . Because of the narrow time win dow, it is 
estimated that only  3% of patients with stroke receive drtPA within the treatment window , and 
there is a clear need for therapies that may  be more widel y used. In addition to rt PA, 
intra-arterial thrombectomy  has also been shown to improve clinical outcomes in stroke patients
[Berkhemer 2015; Goyal 2015; Jovin 2015 ].  Participation in this study will not impact the 
ability  of subjects to receive current standards of care for acute stroke treatment.
5.3. Profile of Previous Experience With Natalizumab
5.3.1. Nonclinical Experience
See the Investigator’s Broch ure for detailed information on nonclinical studies.
5.3.2. Clinical Experience
Natalizumab has been used extensively  in the setting of relapsing remitting MS and CD, both in 
clinical studies involving over 5500 subjects, as well as in the postmarketing setting, with more 
than 9 years of experience and a cumulative exposure of over 200,000 person -years.  As of 
31December 2012, approximately  112,200 patients have been treated with natalizumab 
worldwide.  Therefore, the safety of natalizumab, when given as a 300 mg intravenous (IV) dose 
every  4weeks, has been well characterized in these specific patient populations.  
The efficacy  of natalizumab in relapsing MS patients has been established in 3 controlled 
studies:  a Phase 2 dose- comparison study  as well as 2 Phas e 3 efficacy  and safet y studies.  In 
both Phase 3 studies, treatment with natalizumab delay ed the time to sustained progression in 
disability , substantiall y reduced the frequency of relapses, and markedl y attenuated brain MRI 
measures of inflammation and tissue destruction in subjects with relapsing MS.  Natalizumab as 
monotherap y significantly reduced the risk of disability  progression by  42% relative to placebo.
The most notable complication of treatment is the risk of progressive multifocal 
leukoencephal opath y (PML). PML is an opportunistic viral infection of the central nervous 
system caused by  the John Cunningham virus (JCV). Among the patients who developed PML,
natalizumab exposure ranged from 8 to 90 months ,with the majority  having received >24 
months of treatment. Three established risk factors for the development of PML  have been 
identified: presence of anti -JCV antibodies, longer treatment duration of natalizumab (especiall y 
≥2 years), and prior use of immunosuppressant therap y before initiatio n of natalizumab. 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
20Other risks of natalizumab treatment include a risk for h ypersensitivity  reactions, infections, and 
hepatic injury .  Serious hy persensitivity  reactions (e.g., anaph ylaxis) have occurred at an 
incidence of <1%.
For Phase 2 aexperience, see Section 5.4.3.
5.4. Study Rationale
Stroke is a leading cause of mortality  and serious long -term disability .  There is a substantial 
unmet medical need for new therapies that can improve the outcome of acute ischemic stroke.  
5.4.1. Role of Inflammation in Stroke
The inflammatory  response is closely  coupled to the initial ischemia and activates both the innate 
and adaptive immune s ystems.  I t begins in the intravascular compartment within the first 
6hours (h yperacute period).  The production of reactive ox ygen spe cies activates platelets and 
endothelial cells.  Oxidative stress reduces the vasodilatory  effects of nitric oxide, which is a 
potent inhibitor of platelet aggregation and leukocyte adhesion to the vascular wall.  
Intravascular leukocy tes loosely  adhere to P-selectin, which is upregulated minutes after the 
onset of ischemia, and subsequently  firmly  bind sto adhesion molecules, such as intercellular 
adhesion molecule -1 and VCAM-1.  The activation of matrix metalloproteinase and expression 
of proteases promote blood- brain barrier breakdown, allowing for further influx of leukocy tes.  
After the h yperacute period, DAMPs released from injured neural tissue, including nuclear and 
cytoplasmic neural proteins, trigger cells of the innate and adaptive immune sy stems.   These 
endogenous danger signals are sensed through pattern recognition receptors, such as toll -like 
receptors.  This post -ischemic inflammatory  reaction has been shown to increase infarct volume 
and worsen functional outcomes in preclinical stroke models [Gelderblom 2009 ].  
5.4.2. Preclinical Rationale
The key  role of mononuclear leukocy te-mediated damage in acute stroke is supported by  the fact 
that depletion of these cells or blocking α4 with the rodent- homologue antibody  in experimental 
models reduces brain infiltration of leukocy tes, attenuates expression of cy tokines such as 
interferon -γ and interleukin -6 in brain tissue, reduces stroke size, and improves beh avior in the 
rodent model [Liesz 2011] .  In 1 study , the reduction in stroke volume due to blocking α4β1 was 
greater at Day  7 than Day  1, which is consistent with the delay ed damage induced by  peri-infarct 
inflammation [Liesz 2011 ].  In animal models of experimental brain ischemia, monoclonal 
antibodies targeting α4 integrin have reduced infarct volume and improved functional outcomes 
by approximately  30% compared to placebo.  This effect has been observed in models of 
transient ischemia with treatment administered around the time of reperfusion [Becker 2001; 
Relton 2001 ].  In a preclinical randomized controlled study involving 6 centers, treatment with 
anti-CD49 (targeting α4 integrin) reduced leukocyte invasion and infarct volume in a permanent 
distal middle cerebral artery occlusion model [Llovera 2015] .  
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
215.4.3. Clinical Rationale
Natalizumab has been evaluated in a Phase 2a study  assessing patients with acute ischemic 
stroke.  Study  101SK201 explored the efficacy  and safet y of a single dose of 300 mg 
natalizumab I V administered at ≤6 hours or at >6 to ≤9 hours from when the subjects were last 
known normal ( LKN ).  In this study , 161 subjects (79 subjects in the natalizumab group and 
82subjects in the placebo group) were randomized in the study .  The primary  efficacy  anal ysis 
demonstrated that natalizumab did not decrease acute infarct volume growth defined b y MRI.  
However, on prespecified secondary  and tertiar y clinical endpoints, natalizumab treatment was 
associated with improved clinical outcomes.  More patients had an “excellent” outcome on the 
modified Rankin Scale ( mRS )(defined as a score of 0 or 1) with natalizumab than with placebo 
at Days 30 ( odds r atio [OR] 2.88; 90% confidence interval [ CI]1.20 to 6.93) and 90 (OR 1.48; 
90% CI  0.74 to 2.98).  More patients had an “excellent” outcome on the Barthel Index ( BI; 
defined as a score of ≥95) at Day 90 with natalizumab (OR 1.91; 90% CI 1.07 to 3.41) than 
placebo.  There was no evidence of benefit on the National Institute of Health Stroke Scale
(NIHSS).  Tertiary  clinical endpoints (Stroke Impact Scale -16[SIS-16] , Montreal Cognitive 
Assessment [MoCA]) also supported improved outcomes in the natalizumab group .  In both 
treatment groups, the incidences of death (18% natalizumab versus 16% placebo) and serious 
adverse events ( SAEs; 46% natalizumab versus 46% placebo) were similar, and no increase in 
infections or infusion -related reactions were observed in the n atalizumab group.  Overall, the 
safet y profile was consistent with its use in in the postmarketing setting.
5.5. Rationale for the Treatment Window of ≤24 Hours F rom LKN
In experimental rodent models, immune cell infiltration in the brain parenchy ma following a n 
ischemic stroke occurs predominantly  after 24 hours of lesion onset, reaching its peak at 
approximately  3 day s after the index event [Gelderblom 2009 ].  Congruently, blockage of 
maladaptive immune responses through immune modulatory  treatments as far as 5 day s after 
ische mia onset has been demonstrated to y ield significant beneficial effects in rodent models, 
suggesting that therapies targeting l ymphocy te infiltration after ischemia may  have a prolonged 
therapeutic window [Doyle 2015 ; Shichita 2009] .
A stratif ied randomization process was adopted in Study  101SK201 to evaluate the potential 
time dependency  of treatment effect when administering 300 mg of natalizumab in a 9- hour 
window as compared to placebo.  In this study , half of the subjects in the intent -to-treat 
population were assigned to receive stud y treatment at ≤6 hours from LKN, while the other half 
had study  treatment administered within the > 6 to ≤9 hour window.  Results from 
Study 101SK201 indicated that estimates of treatment effect favored nataliz umab against 
placebo at both treatment windows, with no evidence of time dependency for the treatment 
benefit .  Likewise, the safety  profile of natalizumab treatment was comparable in the ≤6hour 
and the > 6 to ≤9 hour treatment windows, with a small decrea se in the proportion of deaths (21% 
and 15%, respectivel y) and SAEs (47% and 45%, respectivel y) being reported among subjects 
treated in the later treatment window.
Based on these observations, the therapeutic window for natalizumab therapy  appears to be 
greater than 9 hours.  Therefore, in addition to evaluating a ≤9 hour treatment window, 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
22Study 101SK202 will further explore the time dependency  of the treatment effect of natalizumab 
in patients with acute ischemic stroke by enrolling a limited number of subjects within the 
treatment window of > 9to ≤24 hours from LKN.
5.6. Rationale for Dos ing Regimen
Study  101SK201 indicated that a dose of 300 mg natalizumab was associated with improved 
clinical outcomes after stroke. Post hoc anal yses demonstrated that those subjects with greater 
area under the serum concentration versus time curve (AUC ;but not maximum serum 
concentration [ Cmax])following administration of 300 mg )were more likely  to have better 
clinical and MRI defined outcomes compared to placebo treated subjects and subjects with lower 
AUC following 300 mg. For example, higher natalizumab AUC after the 300 mg IV infusion 
was associated with lower MRI -defined infarct volume growth at D ay 30 (p =0.033), and 
subjects in the top tertile of natalizumab AUC had the highest ORfor excellent out come on the 
mRS at Day 90 (OR :3.02; 95% CI: 0.89 to 10.75) and BI at Day  90 (OR:3.00; 95% CI: 0.97 to 
9.99).  Exposure –response modeling predicted that doses in the range of 450 to 600 mg may  be 
associated with improved outcomes relative to the 300-mg do se.
Therefore, Stud y101SK202 will explore this relationship by  evaluating 300-mg and 600- mg
doses administered at 0 Hours in comparison with placebo administered at 0 Hours .  Dosing 
instructions and details regarding administration will be provided in the Directions for Handling 
and Administration (DHA) .  
Doses as high as 6 mg/kg of natalizumab have been studied previously in subjects with MS with 
the highest dose of 697 mg given monthly . The Phase 2b Study  AN100226- 231 evaluated the 
safet y, tolerabilit y, and efficacy  of multiple administrations of natalizumab (3 mg/kg versus 
6mg/kg) given every  28 day s for 6 months in subjects with MS. Monthly  infusions of 
natalizumab at doses of 3 and 6 mg/kg were well tolerated and were associated with a safet y 
profi le similar to that of placebo. There was no significant difference in the incidence of adverse 
events (AEs) between treatment groups. The majority  of AEs in each treatment group were 
reported b y the Investigator as mild or moderate in severit y and not re lated to study  drug.
5.6.1. Rationale for Comparator/Reference Product or Placebo 
The use of placebo is justified because subjects will be receiving the standard of care in addition 
to study  treatment.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
236. STUDY OBJECTIVES AND ENDPOINTS
6.1. Primary Objective and Endpoint
The primary  objective of the study  is to assess the clinical effects of natalizumab versus placebo 
in acute ischemic stroke on clinical measures of functional independence and activities of daily  
living.
The primary  efficacy  endpoint that relates to this objective is a composite global measure of 
functional disability  based on a score of 0 or 1 on the m RSand a score of ≥95 on the BI at Day  
90[Tilley  1996 ]. 
6.2. Secondary Objectives and Endpoints
The secondary  objective of the study  is to explore dose and exposure response , time dependency
of the treatment effect, and the clinical trea tment effects of natalizumab versus placebo in acute 
ischemic stroke on the following measures of independence, activities of daily  living, neurologic 
function, quality  of life, cognition, and safet y and tolerability .
The secondary  endpoints that relate to this objective are:
mRS score at Day  90
BIscore at Day  90
SIS-16 score at Day 90
MoCA score at Day  90
Safety  (incidence and proportion of AEs and SAEs)
NIHSS score at Day 90
6.3. Exploratory Objectives and Endpoints
The exploratory  objective of this study  is to evaluate the effect of natalizumab on measures of 
function, cognition, fatigue ,depression, quality  of life, and pharmacokinetic
(PK) /pharmacody namic (PD) relationships over time.
The exploratory  endpoints that relate to this objective are:
Functional I ndependence Measure (FIM)score at Day 90
Symbol -Digits Modalities Test (SDMT) score at Day  90
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
24Fatigue Severity  Scale (FSS) score at Day  90
Beck Depression Inventory  2 (BDI -2) score
Serum concentrations of natalizumab at selected times after dosing
Blood biomarkers of natalizumab
Subject direct resource use (assessed using a health resource utilization [HRU] 
questionnaire)
EuroQoL EQ -5D-3L (questionnaire)
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
257. STUDY DESIGN
7.1. Study Overview
See Figure 1 for a schematic of the study  design.
This is a Phase 2, multi center, double -blind, placebo -controlled, randomized, dose -ranging, 
3-arm stud y of natalizumab administered ≤24 hours from when the subject was LKN in subjects 
with acute ischemic stroke.  This study  will evaluate the efficacy  and safety of natalizumab over 
a 90-day period.   The study  will be conducted at approximately  67 sites in the United States and 
Europe.
After completing screening assessments and fulfilling the criteria for study  entry , eligible 
subjects in each of 2 treatment windows ( ≤9 hours and >9 to ≤24 hours from L KN) will be 
randomized in a 1:1:1 ratio to 1 of 3 treatment groups, each of which will receive a single dose at 
0 Hours (Day 1)according to one of the following 3 regimens: 600mg IV natalizumab, 
300mgIV natalizumab, or placebo IV.  Post -treatment assessments will be performed at the 
following timepoints:  within 1 hour after the endof the infusion, 12 ± 3hours after the start of 
the infusion , 24 ± 6 hours after the start of the infusion , Day 5,Day 30 (± 5 day s), and the Day 90 
Follow -Up visit(±5 day s).
Participation in this study will not influence the subject’s ability toreceive standard of care 
treatment for stroke, as deemed necessary  by the Investigator.
7.2. Overall Study Duration and Follow -Up
The study  period will consist of Screening, Randomization, Treatment, and Safety  Follow -up 
periods.  Subjects will participate in this study  for approximately  90 day s. 
7.2.1. Screening
Subject eligibility  for the study  will be determined at the time of acute ischemic stroke diagnosis.
7.2.2. Treatment
Eligible subjects will report to the study  site to receive study  treatment ≤24hours from their 
LKN, as described in Section 7.1 .  Approximately  one-third of the subjects will be treated in 
each treatment group.
7.2.3. Follow -Up
Subjects are to return to the study  site for a follow -up visit on Day  30 and Day 90 (Follow -Up 
Visit;the final study  visit ).  If the subject is unable to return to the study  center to complete a
visit in person, t he Day 30 or the Day  90 Follow -Up visitscan be completed over the telephone 
or remotel y, as local regulations allow and pending medical moni tor approval.  
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
26The final study  visit will be the Day  90 Follow -Up and will consist of the collection of AEs, 
SAEs, FIM, mRS, BI, BDI -2, SI S-16, EQ -5D-3L, phy sical/neurological exam ination , vital signs, 
hematology /blood chemistry , serum biomarkers, PD samp ling, PK sampling, anti- natalizumab 
antibodies, NIHSS, MoCA, SDMT, FSS, HRU, andconcomitant medication information .
7.3. Study Stopping Rules
Biogen may  terminate this study  at an y time after informing Investigators.  Investigators will be 
notified by  Biogen or designee if the study  is placed on hold, completed, or closed.  There are no 
prespecified stopping rules.  An independent Data Safety  Monitoring Committee (DSMC) will 
be formed and will review safet y data regularl y.  Details of the DSMC responsibilities will be 
provided in the DSMC charter.
7.4. End of Study
The end of stud y is last subject, last visit for final collection of data.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
278. SELECTION OF SUBJECT S
8.1. Inclusion Criteria
To be eligible to participate in this study , candidates must meet the following eligibili ty criteria 
at Screening or at the timepoint specified in the individual eligibility  criterion listed.  All 
eligibility  assessments must be completed in time for dosing within ≤9 hours or >9 to ≤ 24 hours
of the subject’s LKN:
1.Ability  to understand the purpose and risks of the study  and provide signed and dated 
informed consent and authorization to use protected health information in accordance 
with national and local subject pri vacy  regulations OR consent provided by  an 
independent ph ysician where local regulation allows, and/or provision of informed 
consent b y the subject’s representative in accordance with all local and national 
regulations OR according to the local institution al review board’s (I RB’s)/ethics 
committee’s (EC’s) guidelines OR by  another process compliant with applicable national 
laws and regulations and IRB/EC requirements
2.Aged 18 to 80 y ears,inclusive ,at the time of informed consent
3. Clinical diagnosis of supratentorial acute ischemic stroke defined by LKN ≤24 hours 
prior to study  treatment initiation.  Note:  An acute brain CT or MRI scan must be 
available from the patient’s history  to assess eligibility  for the study  and be consistent 
with the diagnosis of acute ischemic stroke
Note:  The number of subjects enrolling in the treatment window of >9 to ≤24 hour sfrom 
LKN will be limited to no more than 90.
4.Score of 5 to 23 points ,inclusive ,on the NIHSS at Screening for subjects initiating 
treatment ≤9 hours from LKN.   Note:  NIHSS eligibility  must be confirmed within 
60minutes prior to randomization.
5. Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating 
treatment >9 to ≤24 hours from LKN.  Note:  NIHSS eligibility  must be confirme d within 
60minutes prior to randomization.
6.Prior to index stroke, patient was able to perform the following basic activities of daily  
living without assistance:  dressing, eating, walking, bathing, and using the toilet
7.For those subjects who underwent a cranial MRI , there is at least 1 acute infarct with a
diameter of ≥ 2 cm on b aseline b rain diffusion- weighted imaging
8. Subjects of childbearing potential must be willing and able to practice effective 
contraception during the study
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
289.All women of childbearing potential and all men must practice effective contraception 
during the study  and for at least 3 months after their last dose of study  treatment.  For 
further details of contraceptive requirements for this study , please refer to Section 15.5.
8.2. Exclusion Criteria
Candidates will be excluded from stud y entr y if any of the fo llowing exclusion criteria exist at 
Screening , or at the timepoint specified in the individual criterion listed :
1. L acunar or isolated brainstem or cerebellar stroke based on clinical assessment and 
available acute imaging studies performed under the standar d of care .
2.Presence of acute intracranial hemorrhage on acute brain CT or MRI .  However, 
petechial hemorrhages of ≤1 cm are not exclusionary .
3.Severe stroke defined by imaging criteria based on either one of the following
a.ASPECTS score of 0 to 4 based on he ad CT OR
b.Acute infarct volume on MRI  diffusion weighted imaging ≥70mL (cc)
4.Seizure at the onset of stroke
5.Hypotension requiring the use of IV vasopressor support or sy stolic blood pressure 
<90mmHg at the time of randomization
6.Known history  of prior treatment with natalizumab
7.Immunocompromised subjects as determined b y the Investigator, based on medical 
history , phy sical examination, or laboratory  testing, or due to prior or current 
immunosuppressive or immunomodulating treatment
8.Known history  of positive test result for human immunodeficiency  virus (HIV)
9.Known history  of active viral hepatitis B or C .
10.Signs of active herpes simplex ty pe 1 and 2 or varicella within 4 weeks prior to 
randomization
11.Known history  of chronic, recurrent, or recent serious infecti on (e.g., pneumonia, 
septicemia) as determined by  the Investigator within 6 months of randomization
12. S igns and s ymptoms of active or acute infection
13.Abnormal laboratory  values indicative of or known history  of significant medical, 
neurologic (other than stroke), or ps ychiatric disorders or known history  of substance 
abuse that might preclude safe participation in the study  in the opinion of the Investigator
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
2914.Known history of malignant disease within the last 5 y ears, including solid tumors and 
hematological malignancies (with the exception of basal cell and squamous cell 
carcinomas of the skin that have been completel y excised and are considered cured)
15.Inability  to compl y with study requirements
16.Previous registration in this study
17.Other unspecified reasons th at, in the opinion of the Investigator and/or Biogen, make the 
subject unsuitable for enrollment
18.Nursing or pregnant females or females planning to become pregnant during study  
participation
19.Known history  of participation in any  other investigational study that involved treatment 
with an investigational drug within 6 months prior to enrollment
20.Hypersensitivity  reaction to present tissue plasminogen activator treatment
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
309. ENROLLMENT, REGISTRA TION, AND RANDOMIZAT ION
9.1. Screening and Enrollment
Subjects (or their le gally authorized representative [e.g., parent or legal guardian], where 
applicable) must provide informed consent before any screening tests are performed (see 
Section 17.3).  When a subject signs the Informed Consent F orm (ICF), that subject is considered
to be enrolled in the study.  Subjects will not be eligible for rescreening.
Participating stud y sites are required to document all screened candidates initially  considered for 
inclusion in this study .  If a subject is excluded from the study , the reasons for exclusion will be 
documented in the subject’s source documents and on the screening log.
9.2. Randomization and Registration of Subjects
Two separate randomization schemes will be used for subjects in the 2 treatment windows 
(i.e., ≤9 hours from LKN and >9 to ≤24 hours from L KN).  Within each treatment window, 
subjects will be randomized and registered b y an Interactive Voice/Web Response Sy stem 
(IXRS) at Screening , after all Screening assessments have been completed and after the 
Investigator has verified that the subjects are eligible per criteria in Sections 8.1and8.2.  No 
subject may  begin treatment prior to randomization and assignment of a unique subject 
identification number.  Any  subject identification numbers that are assig ned will not be reused 
even if the subject does not receive treatment.
Subjects in each treatment window will be randomized to receive natalizumab 300 mg, 600 mg,
or placebo in a 1:1:1 ratio (see Figure 1 ).  For subjects inthe ≤9 hour treatment window, 
randomization will be stratified by  baseline NIHSS category (NIHSS score 5 to 15 or 16 to 23) ,
tPA use (y es or no), and region; for subjects in the >9 to ≤24 hour treatment window, 
randomization will be stratified by  tPA use (yes or no) and region.
Refer to the Study  Reference Manual for details on registration and randomization.
As confirmation, IXRS will provide the Investigator with written verification of the subject’s 
registration by  e-mail or fax.  Study  treatment prepar ation and administration should commence 
as soon as confirmation of randomization and assignment of a drug kit number is received.
9.3. Blinding Procedures
This is a randomized, double -blinded, placebo -controlled study .
All study  staff will be blinded to the su bject treatment assignments.  To maintain the study  blind, 
it is imperative that subject treatment assignments are not shared with the subjects, their families, 
or an y member of the study  team, either at the study  site or at Biogen.  
Matching placebo vial s will be provided.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3110. DISCONTINUATION OF STUDY TREATMENT AND/OR 
WITHDRAWAL OF SUBJEC TS FROM THE STUDY
10.1. Discontinuation of Study Treatment
Infusion of study treatment must be stopped immediately  and permanently  discontinued for any  
of the following reasons:
The subject is found to be pregnant.  Stud y treatment must be discontinued 
immediately .  Report the pregnancy  according to the instructions in Section 15.4.1 .
The subject experiences a hy persensitivity  or suspected allergic reaction to study  
treatment
Subjec t consent for participation is withdrawn
The subject experiences a medical emergency  that necessitates discontinuation of 
study  treatment
The subject experiences a medical emergency  that necessitates unblinding of the 
subject’s treatment assignment
At the discretion of the Investigator or the Sponsor (Biogen) for medical reasons
The reason for discontinuation of study  treatment must be recorded in the subject’s electronic 
case report form ( eCRF).   For all subjects who discontinue study treatment, safet y dat a will be 
collected at the Day 90 Follow -Up visit .
10.2. Withdrawal of Subjects From Study
Subjects must be withdrawn from the stud y for any of the following reasons:
Subject consent for participation is withdrawn .  
The subject enrolls into another intervention al clinical study  in which an 
investigational treatment or approved therap y for investigational use is administered.
The subject is unwilling or unable to compl y with the protocol.
The reason for the subject’s withdrawal from the study  must be recorded in the subject’s eCRF.  
The subject will be asked to complete earl y termination assessments in person.  If the subject 
cannot complete earl y termination assessments in person, a follow -up phone call or remote visit 
will be made to all subjects who withdraw f rom the study  for purposes of collecting information 
on AEs/SAEs, FIM, mRS, BI, BDI -2, SIS -16, EQ -5D-3 L, physical/neurological exam ination , 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
32vital signs, hematology /blood chemistry , serum biomarkers, PD sampling, PK sampling, anti -
natalizumab antibodies, NI HSS, MoCA, SDMT, FSS, HRU, and concomitant therap y.
For all subjects who withdrew from the study , safety  data will be collected at the Day  90 
Follow -Upor Earl y Termination visit.
Subjects who withdraw from the study will not be replaced.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3311. STUDY TREATMENT U SE
11.1. Regimen
Refer to and follow the DHA.
11.2. Modification of Dose and/or Treatment Schedule
The dose should be followed as described in Section 7.1.  No modifications of dose are allowed.
11.3. Precautions
Subjects will be observed for 1 hour after the study  treatmen t infusion is complete to allow 
monitoring for h ypersensitivity  reactions.
11.4. Compliance
Compliance with treatment dosing is to be monitored and recorded b y site staff.
11.5. Concomitant Therapy and Procedures
11.5.1. Concomitant Therapy
A concomitant therap y is any drug or substance administered between time of informed consent 
or authorization to enroll and completion of assessments at the Day  90Follow -Upvisit (as 
required by the protocol ).  All thromboly tic treatments (i.e., IV andintra-arterial rtPA )and
mechanical thrombectomy that a subject receives are to be recorded as concomitant therap y 
regardless of whether they are given before or after the time of informed consent.
11.5.1.1. Allowed Concomitant Therapy
Concomitant therap y with any of the following is allowed as long as the exclusion criteria 
described in Section 8.2are observed:
Medications necessary  for treatment of AEs according to the discretion of the 
Investigator.
Medications used in standard of care to treat stroke, cardiovascular risk factors, or 
other comorbid conditions, except for disallowed concomitant therapy .
Corticosteroids that are administered by  non-systemic routes (e.g., topical or inhaled).  
Acute use of s ystemic corticosteroids is allowed in this study .
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3411.5.1.2. Disallowed Concomitant Therapy
Concomitant ther apy with any investigational product is not allowed.
11.5.2. Concomitant Procedures
A concomitant procedure is any  therapeutic intervention (e.g., surgery /biopsy , phy sical therap y) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performe d between 
the time the subject is enrolled in the study  and Safety  Follow -Up.  All thromboly tic treatments 
and mechanical thrombectomy that a subject receives are to be recorded as concomitant 
procedures regardless of whether they  are given before or after the time of informed consent.
The use of concomitant therapies or procedures defined above must be recorded on the subject’s 
eCRF, according to instructions for eCRF completion.  All AEs following the administration of 
these therapies or procedures must be documented on the appropriate eCRF, regardless of 
relatedness.
11.6. Continuation of Treatment 
No further provisions are made for access to the study treatment.  If natalizumab is proven to be 
beneficial, all regulatory  requirements regarding post -study  acces s will be met.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3512. STUDY TREATMENT MANA GEMENT
Study  site staff should follow the DHA for specific instructions on the handling, preparation, 
administration, and disposal of the study treatment.  The DHA supersedes all other references 
(e.g., protocol).
Study  treatment must be dispensed only  by a pharmacist or appropriatel y qualified staff.  Stud y 
treatment is to be dispensed only  to subjects enrolled in this study .  Once study  treatment is 
prepared for a subject, it can be administered onl y to that subject.  St udy treatment vials are for 
one-time use onl y; do not use any  study  treatment remaining in the vial for another subject.
12.1. Natalizumab
Natalizumab is supplied as a liquid in 15 -mL vials containing 300 mg of natalizumab per vial.  
Natalizumab drug product con tains recombinant humanized anti -α4 integrin antibody  and 
excipient materials (sodium phosphate monobasic monohy drate, sodium phosphate dibasic 
heptah ydrate, sodium chloride, and pol ysorbate 80).
Natalizumab is manufactured b y Biogen.  
The contents of the natalizumab label will be in accordance with all applicable regulatory 
requirements.  At a minimum, the label will include a study  reference code, study  treatment 
identifier, quantity  of dosage units, lot number, and other pertinent information in accorda nce 
with local law.  The expiry  or use -by date is stored in the interactive response technology  (IRT) 
system, and printable assignment reports are available to site personnel.  Study  treatment should 
not be used after the expiration, expiry , or use -by date .  
12.1.1. Natalizumab Preparation
The individual preparing natalizumab should carefully  review the instructions provided in the 
DHA.
If the packaging is damaged, or if there is an ything unusual about the appearance or attributes of 
the vials or study  treatment, do not use the study  treatment.  The vials in question should be 
saved at the stud y site and the problem immediately reported to Biogen.
12.1.2. Natalizumab Storage
Study  treatment must be stored in a secure location.  
Natalizumab is to be stored at 2°C to 8°C (3 6°F to 46°F), protected from light in a monitored and 
locked refrigerator with limited access.  Study  treatment is not to be frozen.  For the most up -to-
date storage requirements, follow the instructions provided in the DHA.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3612.1.3. Natalizumab Handling and Dispos al
The Investigator must return all used and unused vials of natalizumab as instructed b y Biogen ,
unless approved for onsite destruction.
If any stud y treatment supplies are to be destro yed at the study  site, the institution or appropriate 
site personnel m ust obtain prior approval from Biogen by providing, in writing, the destruction 
policy  or details of the method of destruction.  After such destruction, Biogen must be notified, 
in writing, of the details of the study  treatment destroy ed (e.g., lot or kit numbers, quantities), the 
date of destruction, and proof of destruction.
12.1.4. Natalizumab Accountability
Accountability  for study  treatment is the responsibility  of the Investigator.  The study  site must 
maintain accurate records demonstrating dates and amount of study  treatment received, to whom
study  treatment was dispensed (subject -by-subject accounting), and accounts of any  study  
treatment accidentall y or deliberatel y destro yed or lost.  
Unless otherwise notified, all vials both used and unused must be save d for study  treatment 
accountability .  At the end of the study , reconciliation must be made between the amount of 
study  treatment supplied, dispensed, and subsequently  destroyed, lost, or returned to Biogen.  A 
written explanation must be provided for an y discrepancies.
12.2. Placebo
Placebo is supplied as a liquid in 15- mL vials containing sodium phosphate monobasic 
monohy drate, sodium phosphate dibasic heptah ydrate, sodiu m chloride, and poly sorbate 80.
Placebo is manufactured by  Biogen.
The label will include c onditions for storage and other pertinent information required by  local 
law, such as the lot/kit number and caution statement.  Placebo should not be used after the 
expiration date.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
3713. EFFICACY, PHARMACOKINETIC , AND 
PHARMACODYNAMIC ASSE SSMENTS
See Section 4for the timing of all assessments.
13.1. Clinical Efficacy Assessments
The following clinical tests/assessments will be performed to assess the efficacy  of natalizumab.  
Designation of eligibility  criteria for performing the assessments will be provided in the St udy 
Reference Manual.
mRS:   The mRS measures independence, rather than neurological function, with specific tasks 
pre-and poststroke [ Bonita and Beaglehole 1988 ;Rankin 1957; Rankin 2003; van Swieten 
1988 ].  The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no sy mptoms and 6 
corresponding to death.  Raters will be required to be certified in the use of the mRS .  The mRS
will be completed b y a telephone interview for any subjects who fail to attend their Day 90 
Follow -Up or Earl y Termination visit.  The mRS takes less than 5 minutes to administer.
BI:  The BIconsists of 10 items that measure a person’s daily  functioning, specificall y the 
activities of daily  living and mobility  [Collin 1988 ; Mahoney  and Barthel 1965 ; Wade and Collin 
1988 ].  The items include feeding, moving from whe elchair to bed and return ing, grooming, 
transferring to and from a toilet, bathing, walking on a level surface, going up and down stairs, 
dressing, and maintaining continence of bowels and bladder.  The assessment can be used to 
determine a baseline level of functioning and can be used to monitor change in activities of daily 
living over time.  The items are weighted according to a scheme developed by  the authors.  The 
person receives a score based on whether they  have received help while doing the task.  T he 
scores for each of the items are summed to create a total score up to a maximum of 100.  The 
higher the score, the more “independent” the person is.  The BI takes less than 5 minutes to 
administer.
NIHSS: The NIHSS is a reliable tool for rapidly  evalua ting the effects of acute cerebral 
infarction [Lyden 1999] .  Raters will be required to be certified in the use of the NIHSS.  A 
trained observer rates the subje ct’s ability  to answer questions and perform activities relating to 
level of consciousness, language, visual -field loss, extraocular movement, motor strength, ataxia, 
dysarthria, sensory  loss, and extinction and inattention (formerl y neglect).  There are 1 5items.  
Ratings for each item are scored with 3 to 5 grades, with 0 as normal and a maximum possible 
total severity  score of 42 for all items.  There is an allowance for untestable items.  The test takes 
approximately  10 minutes to complete.   
SIS-16:  The SI S-16 is a 16 -item phy sical dimension instrument that was developed as a brief, 
stand- alone tool for measuring the ph ysical aspects of stroke recovery  [Duncan 2003] .  The 
16physical aspects are rated on a 1 to 5 scale as follows:  not difficult at all (5), a little 
difficult (4), somewhat difficult (3), very  difficult (2), and could not do at all (1).  The SI S-16 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
38takes 5 to 10 minutes to complete and is also available in a proxy version that can be used when 
patients are unable to answer themselves. 
MoCA:   The MoCA is a global cognitive screening test with favorable ps ychometric properties 
[Cumming 2013; Pasi 2013] ; it has been shown to be more sensitive to executive impairment 
than the Mini- Mental State Examination.  I t screens 8 domains:  visuospatial/executive, naming, 
memory , attention, language, abstraction, de layed recall, and orientation.  The assessment takes 
approximately  10 minutes.  The highest possible total score is 30 points, and the assessment is 
available in 31 languages.
FIM :  The FIM instrument is a widely  used functional performance measure develop ed 
specificall y for the inpatient acute rehabilitation population.  I t has been recommended by  the 
Agency  for Health Care Policy  and Research Post -Stroke Rehabilitation panel as a measure of 
activities of daily  living after stroke.  It is an 18- item instru ment graded on a 7 -point ordinal 
scale, with a maximum total score of 126.  The 7 -point ordinal scale indicates the burden of care 
associated with each aspect of function.  The assessment is verbally  administered by  a certified 
rater to the patient or proxy andtakes approximately  30to 60 minutes to complete.   
SDMT:   The SDMT measures Informational Processing Speed in the visual modality .  This is a 
90-second timed test, patient respondent onl y.  Patients are presented with a key  that includes 9
numbers, each paired with a different s ymbol.  Patients must then provide the correct numbers 
that accompan y the symbols.  Both written and oral response versions are used and the SDMT 
takes only  a few minutes to administer (including task instructions).  When used with the MoCA, 
SDMT has been found to improve accuracy  in detecting post -stroke vascular cognitive 
impairment [Dong 2014 ].  Rater certification is required.  
FSS:  The FSS is a 9-item scale which measures the severit y of fatigue and its effect on a 
person ’s activities and lifesty le in patients with a variet y of disorders.   The scale is self- reported 
or verball y administered and takes approximately  3 to 5 minutes to complete.   The items are 
scored on a 7 point scale with 1 = strongl y disagree and 7= strongl y agree.  The minimum total 
score is 9, and the maximum score possible is 63, with the higher the score indicating greater 
fatigue severity .
BDI-2:  The BDI -2 quantifies the severit y of depression that has been evaluated in the setting of 
stroke.  I t is a self -report inventory  and can be self -administered or verball y administered.  This 
instrument rates items on a 4 point scale that ranges from 0 to 3.  Ratings are summed to pr ovide 
a total score ranging from 0 to 63.
Subject direct resource use (HRU questionnaire) :  The HRU questionnaire quantifies the 
amount of time patients spent in various settings of care (e .g., intensive care unit , general 
medical ward, skilled nursing fac ility, long -term care , Home with Support, Home without 
Support, etc), the 30 -day readmission rate, and rehabilitation utilization.
EQ-5D-3 L:  EQ -5D-3L is an instrument that evaluates the generic qualit y of life; it was 
developed in Europe and is widely  used.  The EQ -5D-3L descriptive sy stem is a preference -
based health- related quality  of life measure with 1 question for each of the following 5 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
39dimensions : mobility , self -care, usual activities, pain/discomfort, and anxiety /depression.  This 
scale can be sel f-reported, proxy -respondent, or verbally administered and takes approximately  
10 minutes to complete .
13.2. Pharmacok inetic Assessments
The following tests will be performed to assess the PK of natalizumab:
Serum concentrations of natalizumab at selected times after dosing
13.3. Pharmacodynamic Assessments
The following tests may be performed to assess the PD properties of natalizumab:
Blood biomarkers of natalizumab target engagement
Serum cy tokines and other inflammatory  markers of stroke
Serum samples collected dur ing the stud y ma y be used for other potential or exploratory  
biomarkers related to efficacy  or safet y related outcomes and /ornatalizumab -VLA -4 
pharmacology . 
The purpose of serum sample collection is to develop potential predictive biomarkers throughout 
the study  that may  predict response to treatment or understand disease course and to develop 
potential PD markers through characterization of changes in blood cell transcription induced by  
the study  treatment or disease course. A combination of linear modeling and machine learning 
approaches may  be used to analy ze the data.
Blood samples may  be stored for up to 15 years after study  completion for anal yses.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
4014. SAFETY ASSESSMENTS
Refer to Section 4for the timing of all safet y assessments.
14.1. Clinical Safety Asses sments
The following clinical assessments will be performed to evaluate the safety  profile of 
natalizumab: 
Medical history
Physical examinations and neurological assessments
Vital sign measurements:  temperature, pulse rate, sy stolic and diastolic blood 
pressure, and respiratory  rate
Height and weight measurements
Concomitant therap y and procedure recording
Monitoring of AEs and SAEs
14.2. Laboratory Safety Assessments
The following laboratory tests will be performed to evaluate the safety profile of natalizumab :
Hematology :  Complete blood count with differential and platelet count and absolute 
neutrophil count 
Blood chemistry :  total protein, albumin, creatinine, blood urea nitrogen, uric acid, 
bilirubin (total and direct), alkaline phosphatase, alanine aminotransferase, aspartate 
aminotransferase, gamma- glutamy l-transferase, glucose, calcium, phosphorus, 
bicarbonate, chloride, sodium, and potassium
Anti- natalizumab antibodies
Duplicate samples for laboratory  assessments will be collected as a backup in case th e original 
sample is lost or not evaluable.  All samples listed above will be sent to central laboratories.  
Standard of Care samples will be analy zed locally.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
4115. SAFETY DEFINITIONS, RECORDING , REPORTING, AND
RESPONSIBILITIES
Throughout the course of the stud y, every effort must be made to remain alert to possible AEs.  
If an AE occurs, the first concern should be for the safet y of the subject.  If necessary, 
appropriate medical intervention should be provided.
At the signing of the ICF, each subject or his/he r legally  authorized representative and/or main 
caregiver must be given the names and telephone numbers of study  site staff for reporting AEs 
and medical emergencies.
15.1. Definitions
15.1.1. Serious Pretreatment Event
A serious pretreatment event is any  event that mee ts the criteria for SAE reporting (as defined in 
Section 15.1.3 ) and occurs after the subject or the subject’s representative signs the ICF or after 
enrollment is authorized by  the site or b y another process compliant with applicable national 
laws and regulations and IRB/EC requirements, but before administration of study  treatment.
15.1.2. Adverse Event
An AE is an y untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily  have a causal relationship 
with this treatment.  An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.
Determination of whether an abnormal laboratory  value meets the definition of an AE will be 
made b y the Investigator.  Although abnormal laboratory values are t ypically  not considered 
AEs, the following considerations may  result in an abnormal laboratory  value being considered 
an AE:
A laboratory  test result that meets the criteria for an SAE
A laboratory  test result that requires the subject to receive specific corrective therapy
A laboratory  abnormality that the I nvestigator considers to be clinicall y significant
15.1.3. Serious Adverse Event
An SAE is any  untoward medical occurrence that at any  dose:
Results in death
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
42In the view of the Investigator, places the subject at immediate risk of death (a 
life-threatening event); however, this does not include an event that, had it occurred 
in a more severe form, might have caused death
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Results in a congenital anomaly /birth defect
An SAE may  also be any other medicall y important event that, in the opinion of the Investigator, 
may jeopardize the subject or may  require intervention to prevent one of the other outcomes 
listed in the defin ition above.  (Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency  room or convulsions occurring at home that do not 
require an inpatient hospitalization.)
15.1.4. Prescheduled or Elective Procedures or Routi nely Scheduled Treatments
A prescheduled or elective procedure or a routinely  scheduled treatment will not be considered 
an SAE, even if the subject is hospitalized.  The study site must document all of the following:
The prescheduled or elective procedure or routinely  scheduled treatment was 
scheduled (or was on a waiting list to be scheduled) prior to obtaining the subject’s 
consent to participate in the study .
The condition requiring the prescheduled or elective procedure or routinel y scheduled 
treatment was present before and did not worsen or progress in the opinion of the 
Investigator between the subject’s consent to participate in the study  and the time of 
the procedure or treatment.
The prescheduled or elective procedure or routinely scheduled treatm ent is the sole 
reason for the intervention or hospital admission.
oIf a subject is hospitalized due to local requirements for administration of the 
study  treatment, the hospitalization should not be considered an SAE unless 
one of the requirements in Section 15.1.3 is met.
15.2. Safety Classifications
15.2.1. Investigator Assessment of Events
All events must be assessed to determine the following:
If the event meets the criteria for an SAE as defined in Section 15.1.3 .
The relationship of the event to study  treatment as defined in Section 15.2.2 .
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
43The severit y of the event as defined in Section 15.2.3 .
15.2.2. Relationship of Events to Study Treatment
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study  treatment.
Relationshi p of Event to Study Treatment
Not related An AE will be considered “not related” to the use of the investigational drug if there is 
not a reasonable possibility that the event has been caused by the product under 
investigation.  Factors pointing toward th is assessment include but are not limited to:  the 
lack of reasonable temporal relationship between administration of the drug and the 
event, the presence of a biologically implausible relationship between the product and the 
AE, or the presence of a more likely alternative explanation for the AE.
Related An AE will be considered “related” to the use of the investigational drug if there is a 
reasonable possibility that the event may have been caused by the product under 
investigation.  Factors that point t oward this assessment include but are not limited to:  a 
positive rechallenge, a reasonable temporal sequence between administration of the drug 
and the event, a known response pattern of the suspected drug, improvement following 
discontinuation or dose re duction, a biologically plausible relationship between the drug 
and the AE, or a lack of an alternative explanation for the AE.
15.2.3. Severity of Events
The following definitions should be considered when evaluating the severity  of AEs and SAEs:
Severity of Eve nt
Mild Symptoms barely noticeable to subject or does not make subject uncomfortable; does not 
influence performance or functioning; prescription drug not ordinarily needed for relief of 
symptoms but may be given because of personality of subject.
Modera te Symptoms of a sufficient severity to make subject uncomfortable; performance of daily 
activity is influenced; subject is able to continue in study; treatment for symptoms may be 
needed.
Severe Symptoms cause severe discomfort; symptoms cause incapacita tion or significant impact 
on subject’s daily life; severity may cause cessation of treatment with study treatment; 
treatment for symptoms may be given and/or subject hospitalized.
15.2.4. Expectedness of Events
Expectedness of all AEs will be determined b y Bioge n according to the Investigator’s Brochure. 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
4415.3. Monitoring and Recording Events
15.3.1. Adverse Events
Any AE experienced by  the subject between the time of first dose of stud y treatment (initiation 
of infusion [0 hour]) and the subject’s last study  visit is to be re corded on the eCRF, regardless 
of the severit y of the event or its relationship to study treatment.
15.3.2. Serious Adverse Events
Any SAE experienced by the subject between the time of first dose of study treatment (initiation 
of infusion [0 hour]) and the subjec t’s last study  visit is to be recorded on an SAE form, 
regardless of the severity of the event or its relationship to study  treatment.  SAEs must be 
reported to  within 24 hours as described in Section 15.3.3.  Follow -up information 
regarding an S AE also must be reported with 24 hours. 
Subjects will be followed for all SAEs until the last study  visit.  Thereafter, the event should be 
reported to 
 only if the Investigator considers the SAE to be related to study  treatment.  
Any SAE that i s ongoing when the subject completes or discontinues the study  will be followed 
by the Investigator until the event has resolved, stabilized, or returned to baseline status.  If , after 
the subject’s last study  visit, an SAE occurs in a subject, then the In vestigator should report this 
event to the Sponsor as the Investigator becomes aware of each event.
15.3.3. Immediate Reporting of Serious Adverse Events
In order to adhere to all applicable laws and regulations for reporting an SAE, the study  site must 
formally  notify   within 24 hours of the study  site staff becoming aware of the SAE.  It is 
the Investigator’s responsibility  to ensure that the SAE reporting information and procedures are 
used and followed appropriately .
Reporting Information for SAEs
Any SAE that occurs between the time that the subject has signed the ICF andthe subject’s last 
visit must be reported to  within 24 hours of the study  site staff becoming aware of the 
event.  Thereafter, the event should be reported only  if the Inve stigator considers it related to 
study  treatment.
A report must be submitted to  regardless of the following:
Whether or not the subject has undergone study -related procedures
Whether or not the subject has received stud y treatment
The severit y of the event
The relationship of the event to study  treatment

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
45To report initial or follow -up information on an SAE, fax a completed SAE form; refer to the 
Study  Reference Manual for complete contact information.
15.3.3.1. Deaths
Death is an outcome of an event.  The event that resulted in death should be recorded on the 
appropriate eCRF.  All causes of death must be reported as SAEs within 24 hours of the site 
becoming aware of the event.  The Investigator should make every  effort to obtain and send 
death certificat es and autopsy  reports to .  The term death should be reported as an SAE 
only if the cause of death is not known and cannot be determined.
15.3.4. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are SAEs that are unexpected and 
judged b y the Investigator or Biogen to be related to the study  treatment administered.
Appropriate personnel at Biogen will unblind SUSARs for the purpose of regulatory  reporting.  
Biogen will submit SUSARs (in blinded or unblinded fashion) to regulatory  agencies according 
to local law.  Biogen will submit 
SUSARs to I nvestigators in a blinded fashion.
15.4. Procedures for Handling Special Situations
15.4.1. Pregnancy
Subjects should not become pregnant during the study and up to 3 months aftertheirlast 
dose of study treatment .  If a female subject becomes pregnant, stud y treatment must be 
discontinued immediately .
The Investigator must report a pregnancy  by faxing the appropriate form to  within 
24hours of the study  site staff beco ming aware of the pregnancy  at the fax number found in the 
Study  Reference Manual.  The Investigator or study site staff must report the outcome of the 
pregnancy  to . 
Congenital abnormalities and birth defects in the offspring of male or female s ubjects should be 
reported as an SAE if conception occurred during the study  treatment period.
15.4.2. Overdose
An overdose is an y dose of study  treatment administered to a subject or taken by  a subject that 
exceeds the dose assigned to the subject according to th e protocol.  Overdoses are not considered 
AEs and should not be recorded as an AE on the eCRF; however, all overdoses must be recorded 
on an Overdose form and faxed to  within 24 hours of the site becoming aware of the 
overdose (see Study  Referenc e Manual for fax number) .  An overdose must be reported to 
 even if the overdose does not result in an AE.  If an overdose results in an AE, the AE 
must be recorded on the eCRF .  Ifan overdose results in an SAE, both the SAE and Overdose 

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
46forms must be completed and faxed to .  All study  treatment -related dosing information 
must be recorded on the dosing eCRF.
15.4.3. Medical Emergency
In a medical emergency  requiring immediate attention, study site staff will apply  appropriate 
medical interventio n, according to current standards of care.  The Investigator (or designee) 
should contact the study ’s Medical Monitor .  Refer to the Study  Reference Manual’s Official 
Study  Contact L ist for complete contact information.
15.4.3.1. Unblinding for Medical Emergency
In a medical emergency  when knowledge of the subject’s treatment assignment may  influence 
the subject’s clinical care, the I nvestigator and, if applicable, designated personnel at Biogen 
may access the subject’s treatment assignment by  IRT.  The Investigator must document the 
reasons for unblinding in the subject’s source documents.  The Investigator is strongl y advised 
not to divulge the subject’s treatment assignment to any  individual not directly  involved in 
managing the medical emergency , nor to personnel 
involved with the analy sis and conduct of the 
study .  The Investigator can contact Biogen or designee to discuss such situations.
15.5. Contraception Requirements
All women of childbearing potential must practice effective contraception during the stud y and 
for at least 3 months after their last dose of stud y treatment.  
For the purposes of this study , women who do not meet one of the following criteria listed below 
are considered to be ph ysiologicall y capable of becoming pregnant and are, therefore, defined as 
women of childbearing potential:
Postmenopausal
o12
months of natural (spontaneous) amenorrhea without an alternative 
medical cause
o6weeks after surgical bilateral oophorectom y with or without hy sterectomy
Posthy sterectomy
Female surgical sterilization (e. g., bilateral tubal ligation)

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
47For the purposes of the study , highl y effective contraception is defined as contraception that 
achieves a failure rate of less than 1% when used consistently  and correctly , and includes the 
following:
For females:
Established use of oral, intravaginal, or transdermal combined (estrogen and 
progestogen containing) hormonal methods of contraception associated with the 
inhibition of ovulation.
Established use of oral, injected, or implanted progestogen -only hormonal methods of 
contraception associated with the inhibition of ovulation. 
Placement of an intrauterine device or intrauterine hormone -releasing system.
Bilateral tubal occlusion.
For female subjects participating in the stud y, male sexual partners must have 
undergone surgi cal sterilization with the appropriate postvasectom y documentation of 
the absence of sperm in the ejaculate.
For males:
Effective male contraception includes a vasectomy with negative semen analysis at 
follow -up. 
True abstinence, when this is consistent w ith the preferred and usual lifest yle of the subject, can 
be considered a highl y effective method of contraception based on the eva luation of the 
Investigator who should also take into consideration the duration of the clinical study .  Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, postovulation methods) and withdrawal are 
not considered acceptable methods of contraception.
Pregnancy  reporting is described in Section 15.4.1 .
15.6. Safety Responsibilities
15.6.1. The Investigator
The Investigator’s respons ibilities include the following:
Monitor and record all AEs, including SAEs, regardless of the severity  or relationship 
to study  treatment.
Determine the seriousness, relationship, and severity  of each event.
Determine the onset and resolution dates of eac h event.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
48Monitor and record all pregnancies and follow up on the outcome of the pregnancy  in 
female subjects.
Complete an SAE form for each SAE and fax it to  within 24 hours of the 
study  site staff becoming aware of the event.
Pursue SAE follow-u p information activel y and persistently.  Follow -up information 
must be reported to 
 within 24 hours of the study  site staff becoming aware 
of new information.
Ensure all AE and SAE reports are supported b y documentation in the subjects’ 
medical r ecords.
Pursue AE follow -up information, if possible, until the event has resolved or become 
stable.
Report SAEs to local IRB/ECs, as required b y local law.
15.6.2. Biogen 
Biogen’s responsibilities include the following:
Before stud y site activation and subject e nrollment, the Clinical Monitor is 
responsible for reviewing with study  site staff the definitions of AE and SAE, as well 
as the instructions for monitoring, recording, and reporting AEs and SAEs.
Biogen is to notify  all appropriate regulatory  authorities, IRBs, central ECs, and 
Investigators of SAEs, as required b y local law, within required time frames.
Safety  data will be provided to the DSMC for review of all AEs and key  laboratory  
tests for all subjects prior to completion of Study 101SK202. 

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
4916. STATISTIC AL METHODS AND DETERMINATION OF
SAMPLE SIZE
The objectives of the study  and the endpoints to be anal yzed are listed in Section 6.
16.1. Efficacy
16.1.1. Analysis Population
The efficacy anal ysis will include subjects who are randomized and have received the entire 
infus ion of study  treatment.
16.1.2. Methods of Analysis
Unless otherwise specified, continuous variables will be summarized using summary  statistics 
(mean, standard deviation, median, minimum, and maximum) by  treatment group, and 
categorical variables will be presente d using frequency  distributions by  timepoint and treatment 
group.  Point estimates and 95% CIs will be provided where applicable. 
Subgroup anal ysis by  key factors (including baseline NIHSS category and tPA use )will be
performed for selected efficacy  endp oints.
16.1.2.1. Analysis of the Primary Endpoint
The primary  endpoint is a global composite of an excellent outcome on the mRS (score of 0 or 1) 
and an excellent outcome on the BI (score of at least 95) at Day  90.  The primary  anal ysis will be 
based on a Generalize d Estimating Equation model and logit link function assuming a common 
ORof natalizumab versus placebo across 2 components of the endpoint :the proportion of 
subjects with an excellent outcome onthemRS and the proportion of subjects with an excellent 
outcome on the BI .  The model will include covariates of treatment window ( ≤9 hours from LKN 
vs.>9 to ≤24 hours from LKN), baseline NIHSS category ,and tPA use .  The interaction between
treatment and treatment window will be assessed to determine whether the data of the 
2treatment windows can be pooled.  If no t, then data from the >9 to ≤24 hour window will be 
excluded from the anal ysis population of the primary  endpoint and will be anal yzed separatel y.  
The global OR of natalizumab (2 doses combined) and CIs will be provided . 
Sensitivity  analy ses will be perf ormed to evaluate the impact of missing data, and the missing 
data handling will be specified in the st atistical analy sis plan (SAP).
Similar analyses for other time points, key  subgroups, and each dose versus placebo will be 
performed.  The details will be provided in the SAP.
16.1.2.2. Analysis of the Secondary Endpoints
The same anal ysis population for the primary  endpoint as described in Section 16.1.2.1 will 
apply  tothe secondary  endpoints. The same covariates used in the final modeling of the primary  
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
50endpoint will be adopted in all statistical models for the secondary  endpoints described in this 
section.
16.1.2.2.1. mRS and BI at Day 90
The distribution of mRS at Day  90 will be analy zed by  Van Elteren ’s test.  The proportion of 
subjects who have excellent outcome in mRS (score of 0 or 1) at Day  90 will be anal yzed by 
logistic regression.
The proportion of subjects with excellent outcome on mRS at other timepoints (Day  30, Day  5) 
will be anal yzed similarly .  The mRS at each visit will also be anal yzed using a mixed- effects 
model for repeated measures with treatment and treatment b y visit intera ction as explanatory  
variables.
The proportion of subjects who have an excellent outcome on the BI (score of at least 95) at Day  
90 will be anal yzed by logistic regression.
The proporti on of subjects with an excellent outcome on the BI at other time points (Day  30, Day  
5) will be anal yzed similarly .  The BIat each visit will also be anal yzed using a mixed- effects 
model for repeated measures with treatment and treatment –by-visit interacti on as explanatory  
variables.
16.1.2.2.2. SIS-16 and MoCA at Day 90
Summary  statistics of SIS -16 and MoCA at each visit will be presented by treatment group using 
observed data.
SIS-16 and MoCA at each visit will be analy zed by  a mixed -effects model for repeated measur es 
with treatment and treatment by  visit interaction as explanatory  variables. Treatment contrasts at 
Day 90 will be derived. 
In addition, MoCA assessments will be presented using summary  statistics for the following 
categories: <10 (severe cognitive impairment), 10 to 17 (moderate cognitive impairment), and 
≥18 (mild cognitive impairment).
16.1.2.2.3. NIHSS at Day 90
The change in NIHSS score from baseline at each visit will be analy zed by a repeated -measures 
mixed model with treatment and treatment b y visit interac tion as explanatory  variables.  
Treatment contrasts at Day  90 and other timepoints will be derived. 
The proportion of subjects who have an NIHSS score of 0 or 1 or who have demonstrated at least 
an 8-point improvement from baseline at Day  90 will be anal yzed by  logistic regression, 
adjusting for baseline NIHSS category and tPA use. 
NIHSS at other timepoints will be analy zed similarly .
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5116.1.2.2.4. Dose -Response and Exposure -Response
In addition to the estimation of treatment effect of each dose versus placebo, trend testing 
[Armitage 1955
; Cochr an 1954 ]ofa monotonically  increasing dose response in proportion of 
excellent outcome on mRS and BIwill be performed. Exposure -response models, including E max
model of natalizumab, will be explored. The details will be provided in the SAP.
16.1.2.3. Additional/Exploratory Endpoints Analysis
Analy ses for exploratory  efficacy  endpoints will be provided in the SAP.
16.2. Pharmacok inetics
16.2.1. Analysis Population
Subjects who have received natalizumab at the 0 Hours Visit and had at least 1 measurable 
sample collected for the determination of natalizumab concentrations will be included in the 
analysis.
16.2.2. Methods of Analysis
Serial natalizumab concentrations w ill be measured during the stud y.  Summary statistics for the 
concentration values w ill be calculated at each collection timepoint, and the mean concentrations 
(±standard error [SE]) w ill be plotted over time on both linear and logarithmic scale s.  Plots for 
individual investigational sites w illalso be produced.
PK parameters w ill be calculated using noncompartmental method s .
Noncompartmental estimations of the various parameters w ill be calculated using Model 202 
(noncompartmental IV infusion) in the . Calculations w ill be 
performed using a “linear up/log down” algorithm, with a 1-hour infusion assumed. Points for 
the 
determination of terminal rate constants w ill be selected manually .Summary  statistics for 
each PK parameter w ill be calculated. The following PK parameters w ill be determined for this 
study :
 C max
Time to C max (tmax)
Area under 
the serum concentration v ersus time curve from dosing (time=0) to 
120hours after dosing (AUC 0
-120)
Area under the serum concentration v ersus time curve from dosing (time=0) to 
672hours after dosing (AUC 0-672)
Area und er the serum concentration v ersus time curve from dosing (time=0) to 
2160 hours after dosing (AUC 0-2160) 

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
52Area under the serum concentration v ersus time curve, from dosing (time=0) to last 
measurable concentration (AUC 0-last)
Half-life (t ½)
Time of last me asurable concentration (tlast)
Volume of distribution (V)
Clearance (CL)
Concentrations reported as below the limit of quantification at any  time after dosing w ill be 
treated as missing. The actual times of sample collection (and not the protocol -specifie d times) 
will be used in the calculation of all parameters.
16.3. Pharmacodynamics
16.3.1. Analysis Population
Subjects who have received theentire infusion of study  treatment and have at least 
1postbaseline assessment of the parameter being anal yzed will be included in the PD analy sis.
16.3.2. Methods of Analysis
Summary  statistics for α4- integrin saturation include the following :
Maximum % saturation [R max], time to R max [TR max]
Percent saturation pre -dose [R pre-dose] and percent saturation at the end of the dosing 
interval [R 672] were calculated. 
The mean % satu ration values (±SE) were plotted over time for both the entire study  population 
and the individual dosing groups.
16.4. Safety
16.4.1. Analysis Population
The safet y analysis will include subjects who are randomized and have received an y portion of 
the infusion of study treatment.
16.4.2. Methods of Analysis
No formal statistical testing will be performed on the safet y data.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5316.4.2.1. Adverse Events
The incidence of treatment -emergent AEs will be tabulated b y treatment group, severit y, and 
relationship to study  treatment.  The tabular sum maries will include incidence by  system organ 
class and b y preferred term.  SAEs and AEs resulting in stud y withdrawal will be summarized by  
treatment group.
Treatment -emergent AEs are those defined as having onset after the start of study  treatment, or a 
sign, s ymptom, or diagnosis that worsens since the event was previously  reported.  For the 
analysis of incidence by  severit y, the occurrence of the AE with the greatest severity will be 
used, and a subject will be counted onl y once and only  in the category of the greatest severit y for 
each event.  For the analysis of incidence b y relationship to study  treatment, the occurrence of 
the AE with the strongest relationship to study  treatment will be used ,and a subject is counted 
only once and onl y in the category  of the strongest relationship to study  treatment for each event.
16.4.2.2. Clinical Laboratory Results
Clinically  relevant abnormalities for laboratory  parameters will be identified by  treatment group 
using shift tables and evaluated for their clinical relevance.
16.4.2.3. Vital Signs
The anal ysis of vital signs will focus on the incidence of clinically  relevant abnormalities by  
treatment group.  
16.5. Interim Analyses
An interim futility  anal ysis may beperformed after 50% of the study  population has completed 
the Day  30assess ment. No interim stopping rules for superiorit y will be applied.
16.6. Sample Size Considerations
A sample size of 270 (90 per treatment group) will provide at least 88% probability  for the point 
estimate of the ORfor the primary  comparison of natalizumab (dos e groups combined) versus 
placebo on the global composite measure at Day 90 to exceed 1.3 in both treatment windows 
(i.e., same efficacy  for subjects being treated ≤9 hours and >9 to ≤24 hours from LKN),
assuming a true OR of 1.8 as observed in Study 101SK 201.  Adopting a conservative assumption 
of a 50% reduction intreatment efficacy  in the >9 to ≤24 hour treatment window when compared 
to the ≤9 hour treatment window, this probability  will be at least 80%.  An OR of ≥1.3 on the 
global outcome measure is c onsidered to be clinically  meaningful based on the effect of tPA in 
the 3- to 4.5 -hour time window.  At this sample size, the probability  of observing a point 
estimate exceeding 1.3, if the true ORis ≤1(i.e., the false positive rate), is less than 0.2.  In 
addition, if the true OR of the higher dose versus placebo is 3.0 ,as observed in the subgroup 
with exposure above the median in Study 101SK201, the probability  of observing an OR of ≥1.3 
when comparing the 600 -to 300 -mg dose is at least 7 4%.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5417. ETHICAL R EQUIREMENTS
Biogen and  and the I nvestigator must comply  with all instructions, regulations, and 
agreements in this protocol and applicable International Co uncil on Harmonisation (I CH) and 
Good Clinical Practice (GCP) guidelines and conduct the st udy according to local regulations.
The Investigator may  delegate responsibilities for study -related tasks where appropriate to 
individuals sufficiently  qualified by  education, training, and experience, in accordance with 
applicable ICH and GCP guidelines.   The Investigator should maintain a list of the appropriately  
qualified persons to whom significant stud y
-related duties have been delegated.
17.1. Declaration of Helsink i
This study  will be performed in alignment with the ethical principles outlined in the Dec laration 
of Helsinki.
17.2. Ethics Committee
The Investigator must obtain ECapproval of the protocol, I CF, and other required study  
documents prior to starting the stud y.  The Sponsor or designee will submit documents on behalf 
of the investigational sites in countries other than the US.
If the Investigator makes any  changes to the I CF, Biogen must approve the changes before the 
ICF is submitted to the EC .  A copy  of the approved I CF must be provided to Biogen.  After 
approval, the ICF must not be altered withou t the agreement of the relevant ECand Biogen.
It is the responsibility  of the I nvestigators to ensure that all aspects of institutional review are 
conducted in accordance with current applicable regulations.
Biogen must receive a letter documenting ECapproval, which specificall y identifies the 
protocol, protocol number, and ICF, prior to the initiation of the study .  Protocol amendments 
will be subject to the same requirements as the original protocol.
A progress report must be submitted to the ECat requ ired intervals and not less than annuall y.
At the completion or termination of the study , the investigational site must submit a close -out 
letter to the ECand Biogen.
17.3. Subject Information and Consent
Prior to performing an y study-related activities under t his protocol, including screening tests and 
assessments, written informed consent with the approved ICF must be obtained from the subject 
or subject’s legall y authorized representative (e.g., parent or legal guardian), as applicable, in 
accordance with local practice and regulations.  

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
55The background of the proposed study , the procedures, the benefits and risks of the study , and 
that study  participation is voluntary  for the subject must be explained to the subject (or the 
subject’s legall y authorized repres entative).  The subject must be given sufficient time to 
consider whether to participate in the study .
A cop y of the signed and dated ICF must be given to the subject or the subject’s legall y 
authorized representative.  The signed and dated ICF will be ret ained with the study  records.  
Local regulations must be complied with in respect to the final disposition of the original (wet 
signature) and copies of the signed and dated ICFs.
Confirmation of informed consent must also be documented in the subject’s me dical record.
17.4. Subject Data Protection
Prior to any  testing under this protocol, including screening tests and assessments, candidates 
must also provide all authorizations required b y local law (e.g., Protected Health Information 
authorization in North Amer ica).
The subject will not be identified by  name in the e CRF or in an y study reports, and these reports 
will be used for research purposes only .  Biogen, its partners and designees, ECs, and various 
government health agencies may  inspect the records of thi s study .  Every  effort will be made to 
keep the subject’s personal medical data confidential.
17.5. Compensation for Injury
Biogen maintains appropriate insurance coverage for clinical studies and will follow applicable 
local compensation laws.
17.6. Conflict of Inter est
The Investigators should address an y potential conflicts of interest (e.g., financial interest in 
Biogen or ) with the subject before the subject makes a decision to participate in the 
study .
17.7. Registration of Study and Disclosure of Study Resul ts
Biogen will register the study  and poststudy  results regardless of outcome on a publicly  
accessible website in accordance with the applicable laws and regulations.

Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5618. ADMINISTRATIVE PROCE DURES
18.1. Study Site Initiation
The Investigator must not screen an y subj ects prior to completion of a study initiation visit, 
conducted b y Biogen.  This initiation visit will include a detailed review of the protocol and 
study  procedures.
18.2. Quality Assurance
During and/or after completion of the study , quality  assurance officers named by  Biogen or the 
regulatory  authorities may  wish to perform onsite audits or inspections.  The Investigator will be 
expected to cooperate with any  audit or inspection and to provide assistance and documentation 
(including source data) as requested.
18.3. Monitoring of the Study
The Investigator must permit study -related monitoring b y providing direct access to source data 
and to the subjects’ medical histories.
The Clinical Monitor will visit the I nvestigator at regular intervals during the study  and after the 
study  has completed, as appropriate.
During these visits, eCRFs and supporting documentation related to the study  will be reviewed 
and an y discrepancies or omissions will be resolved.  
Monitoring visits must be conducted according to the applicable I CH and GCP guidelines to 
ensure protocol adherence, quality  of data, study  treatment accountability , compliance with 
regulatory  requirements, and continued adequacy  of the investigational site and its facilities.
18.4. Study Funding
Biogen is the Sponsor of the study  and is funding the study .  All financial details are provided in 
the separate contracts between the institution, I nvestigator, and Biogen.  
18.5. Publications
Details are included in the clinical study agreement for this study .
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5719. FURTHER REQUIREMENTS AND GE NERAL INFORMATION
19.1. External Contract Organizations
A CRO will be responsible for all administrative aspects of this study  including but not limited to 
study  initiation, monitoring, management of AEs, and data management.
19.1.1. Contract Research Organization 
A CR O will be responsible for administrative aspects of the study  including but not limited to 
study  initiation, monitoring, and management of SAE reports and data management.  Before 
subjects are screened at each study  site, the CRO will review study  responsibilities with the 
Investigators and other study site staff, as appropriate.
19.1.2. Interactive Response Technology
IRT will be used in this study .  Before subjects are screened or enrolled, the I RT vendor will 
provide each study  site with the necessary  training, a user manual, and access rights to the 
system.
19.1.3. Remote Data Capture
Subject information will be captured and managed by  study  sites on eCRFs by  a remote data 
capture (RDC) tool developed and supported b y the RDC vendor and configured b y Biogen.
19.1.4. Central Lab oratories for Laboratory Assessments
A central laboratory  has been selected by  Biogen to analy ze all hematology  and blood chemistry , 
PKsampling , and immunogenicity  samples collected for this study .  Standard of Care samples 
will be anal yzed locally .
Dupli cate samples for laboratory  assessments will be collected as a backup in case the original 
sample is lost or not evaluable.
19.1.5. Central Facility for Other Assessments
A central facility  has been selected by  Biogen to perform imaging assessments for this study .  
19.2. Study Committees
19.2.1. Advisory Committee
An advisory  committee will be formed to provide scientific and medical direction for the stud y 
and to oversee the administrative progress of the study .  The advisory  committee will meet at 
regular intervals to monitor subject accrual and to monitor compliance with the protocol at 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
58individual study sites.  The advisory  committee will be blinded to subject treatment assignments.  
The advisory  committee will determine whether the study  should be stopped or amended for 
reasons other than safety .
Members of the advisory committee will include the Medical Director, the Clinical Operations 
Lead, and the Project Statistician from Biogen (and/or their designees), as well as participating 
Investigators who will be appointed by  Biogen based on relevant expertise.  Biogen will 
designate one of the participating Investigators to be the chairperson of the advisory  committee.
The Ongoing Data Review Committee will have an Ongoing Data Review Plan that is separate 
from the DSMC.
19.2.2. Independ ent Data Safety Monitoring Committee 
An independent DSMC will be formed to review data regularl y to assess safet y and risk -benefit 
and recommend appropriate modification to the study  or termination of the study .  The DSMC 
receives reports of all SUSARs, A Es, and key  laboratory  tests and meets throughout the stud y at 
regular timepoints described in the DSMC charter.
19.3. Changes to Final Study Protocol
All protocol amendments must be submitted to the ECand regulatory  authorities if required b y 
local law.  Proto col modifications that affect subject safet y, the scope of the investigation, or the 
scientific quality  of the study  must be approved by the EC before implementation of such 
modifications to the conduct of the study .  If required by  local law, such modific ations must also 
be approved b y the appropriate regulatory  agency  prior to implementation.
However, Biogen may , at any  time, amend this protocol to eliminate an apparent immediate 
hazard to a subject.  In this case, the appropriate regulatory  authorities w ill be notified 
subsequent to the modification.
In the event of a protocol modification, the I CF may  require similar modifications (see 
Section 17).
19.4. Ethics Committee Notification of Study Completion or Termination
Where required, the regulatory  authorities and ECs must be notified of completion or termination 
of this study , and sent a copy  of the study  synopsis in accordance with necessary  timelines.
19.5. Retention of Study Data
The minimum retention time for study  records will meet the strictest standard applic able to that 
site, as dictated b y any institutional requirements or local laws or regulations.  Prior to 
proceeding with destruction of records, the Investigator must notify  Biogen in writing and 
receive written authorization from Biogen to destroy  study  records.  In addition, the I nvestigator 
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
59must notify  Biogen of any  changes in the archival arrangements including but not limited to 
archival at an offsite facility  or transfer of ownership if the I nvestigator leaves the site.
19.6. Study Report Signatory
Biogen w ill designate one of the participating Study  Investigators as a signatory  for the study  
report.  This determination will be made by several factors, including but not limited to, the 
Investigator ’s experience and reputation in the studied indication; the I nvestigator ’s contribution 
to the study  in terms of design, management, and/or subje ct enrollment; or by  other factors 
determined to be relevant by  Bioge n.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6020. REFERENCES
Armitage P. Tests for linear trends in proportions and frequencies. B iometrics. 1955;11:375 -86.
Becker K, Kindrick D, Relton J, et al. Antibody  to the a4 Integrin Decreases I nfarct Size in 
Transient Focal Cerebral Ischemia in Rats. Stroke. 2001;32:206-11.
Berkhemer OA, Fransen PSS, Beumer D, et al. A Randomized Trial of I ntraarterial Treatment 
for Acute Ischemic Stroke. The New England journal of medicine. 2015;372:11 -20.
Bonita R, Beaglehole R. Recovery of motor function after stroke. Stroke. 1988;19(12):1497 -500.
Cochran WG. Some methods of strengthening the common x2 test s. Biometrics. 1954;10:417 -
51.
Collin C, Wade DT, Davies S, et al. The Barthel ADL Index: a reliability  study . Int Disabil Stud. 
1988;10(2):61 -3.
Cumming TB, Churilov L, Linden T, et al. Montreal Cognitive Assessment and Mini -Mental 
State Examination are both valid cognitive tools in stroke. Acta Neurol Scand. 2013.
Dong Y, Slavin MJ, Chan BP, et al. Improving screening for vascular cognitive impairment at 
three to six months after mild ischemic stroke and transient ischemic attack. I nternational 
Psychogeri atrics. 2014;26(05):787-93.
Doyle KP, Quach LN, Solé M, et al. B -lymphocy te-mediated delay ed cognitive impairment 
following stroke. J Neurosci. 2015;35(5):2133-45.
Duncan PW, Lai SM, Bode RK, et al. Stroke Impact Scale- 16: A brief assessment of phy sical 
function. Neurology . 2003;60(2):291-6.
Gelderblom M, Ley poldt F, Steinbach K, et al. Temporal and spatial dy namics of cerebral 
immune cell accumulation in stroke. Stroke. 2009;40(5):1849-57.
Goyal M, Demchuk AM, Menon BK, et al. Randomized Assessment of Rapi d Endovascular 
Treatment of Ischemic Stroke. The New England journal of medicine. 2015;372:1019 -30.
Heuschmann PU, Di Carlo A, Bejot Y, et al. Incidence of stroke in Europe at the beginning of 
the 21st century . Stroke. 2009;40(5):1557 -63.
Jauch EC, Saver J L, Adams HP, et al. Guidelines for the earl y management of patients with 
acute ischemic stroke: a guideline for healthcare professionals from the American Heart 
Association/American Stroke Association. Stroke. 2013;44(3):870-947.
Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy  within 8 Hours after Sy mptom Onset in 
Ischemic Stroke. The New England journal of medicine. 2015;372:2296 -306.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
61Liesz A, Zhou W, Mracsko  E, et al. Inhibition of ly mphocy te trafficking shields the brain 
against deleterious neuroinfla mmationnafter stroke. Brain : a journal of neurology . 
2011;134:704-20.
Llovera G, Hofmann K, Roth S, et al. Results of a preclinical randomized controlled multicenter 
trial (pRCT): Anti-CD49d treatment for acute brain ischemia. Science translational medici ne. 
2015;7(299).
Lyden P, Lu M, Jackson C, et al. Underl ying structure of the National Institutes of Health Stroke 
Scale: results of a factor anal ysis. NINDS tPA Stroke Trial Investigators. Stroke. 
1999;30(11):2347 -54.
Mahoney  FI, Barthel DW. Functional ev aluation: the Barthel index. Md State Med J. 
1965;14:61-5.
Pasi M, Salvadori E, Poggesi A, et al. Factors predicting the Montreal cognitive assessment 
(MoCA) applicability and performances in a stroke unit. J Neurol. 2013.
Rankin J. Cerebral vascular accid ents in patients over the age of 60. II. Prognosis. Scott Med J. 
1957;2(5):200 -15.
Rankin SC. Assessment of response to therap y using conventional imaging. Eur J Nucl Med Mol 
Imaging. 2003;30(Suppl 1):S56- S64.
Relton JK, Sloan KE, Frew EM, et al. Inhibition of a4 Integrin Protects Against Transient Focal 
Cerebral Ischemia in Normotensive and Hy pertensive Rats. Stroke. 2001;32:199 -205.
Roger VL, Go AS, Llo yd-Jones DM, et al. Heart disease and stroke statistics --2011 update: a 
report from the American Heart A ssociation. Circulation. 2011;123(4):e18 -e209.
Shichita T, Sakaguchi R, Suzuki M, et al. Post- ischemic inflammation in the brain. Front 
Immunol. 2012;3:132.
Shichita T, Sugiy ama Y, Ooboshi H, et al. Pivotal role of cerebral interleukin -17-producing 
gammade ltaT cells in the delay ed phase of ischemic brain injury . Nat Med. 2009;15(8):946-50.
Tilley  BC, Marler JM, Geller NL, et al. Use of a Global Test for Multiple Outcomes in Stroke 
Trials With Application to the National Institute of Neurological Disorders a nd Stroke t -PA 
Stroke Trial. Stroke. 1996;27:2136 -42.
Truelsen T, Piechowski -Jóźwiak B, Bonita R, et al. Stroke incidence and prevalence in Europe: a 
review of available data. Eur J Neurol. 2006;13(6):581-98.
van Swieten JC, Koudstaal PJ, Visser MC, et al. Interobserver agreement for the assessment of 
handica p in stroke patients. Stroke. 1988;19(5):604 -7.
Wade DT, Collin C. The Barthel ADL Index: a standard measure of ph ysical disability ? Int 
Disabil Stud. 1988;10(2):64-7.
Protocol 101SK202 Version 3.0
ACTION II Study
CONFIDENT IAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6221. SIGNED AGREEMENT OF THE STUDY PROTOCOL
I have read the foregoing protocol, “ A Multicent er, Double -Blind, Placebo- Controlled, 
Randomized, Parallel- Group, Dose -Ranging Study  to Evaluate the Safety  and Efficacy  of 
Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke ,” and agree to conduct the study  
according to the protocol and the applic able ICH guidelines and GCP regulations, and to inform 
all who assist me in the conduct of this study  of their responsibilities and obligations.
____________________________________________________
Investigator’s Signature Date
____________________ ________________________________
Investigator’s Name (Print)
____________________________________________________
Study  Site (Print)
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
1Biogen MA Inc.
250 Binney Street
Cambridge, MA  02142
United States
Biogen Idec Research Limited
Innovation House
70 Norden Road
Maidenhead Berkshire
SL6 4AY
United Kingdom
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol
 101SK202/[STUDY_ID_REMOVED]
A Multicenter, Double -Blind, Placebo- Controlled, Randomized, Parallel- Group, Dose -Ranging 
Study
 to Evaluate the Safety and E fficacy  of Intravenous Natalizumab (BG00002) in Acute 
Ischemic Stroke
Version 3.0
Date:  03 May 2017
EUDRA CT Number :  2015-004783-11
Version 3.0 of the protocol has be en prepared for this amendment, which supersedes Version 2.0 
(dated 15 December 2016) .

Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
2PRIMARY REASON FOR AMENDMENT
The primary  reason for this amendment to Protocol 101SK202 is to correct an error in the 
pharmacokinetic (PK)/pharmacod ynamic (PD) sampling times.  New text is shown in bold type; 
deleted text is shown with a strikethrough .
Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
3Section 4.2, Schedule of Activities
Now reads:
Table 1: Schedule of Activities for Study 101SK202
Tests and Assessments Screening1,20 Hours2
(Day 1)Within 1 Hour 
After Start End of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination4
±5 Days
Informed consent X
Confirm eligibility X
Demographics and medical 
history5X
Physical and neurological 
examinationX X X X X
Vital signs6X X X X X X X
Height (if available) and weight X (anytime from Screening to Day 5 Visit)
Urine pregnancy test7X
Hematology and blood 
chemistryX X X X X X
Serum biomarkers X X X X X X
PD sampling X X X X X X X
PK sampling X X X X X X X
Blood sample for 
anti-natalizumab antibodiesX X X
NIHSS X X2X X X X
mRS X8X X
BI X X X
SIS-16 X9X X
MoCA X X X
Functional I ndependence 
MeasureX X
SDMT X X X
Fatigue Severity Scale X9X X
Beck Depression I nventory 2 X9X X
HRU questionnaire X X X
EQ-5D-3L X X X
Study treatment administration10X
Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
4Tests and Assessments Screening1,20 Hours2
(Day 1)Within 1 Hour 
After Start End of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination4
±5 Days
Stroke subtype classification11X
SAE reporting Record as per Section 15.3.2of the protocol
AE reporting Record as per Section 15.23.1of the protocol
Concomitant medications Record as per Section 11.5 of the protocol
Concomitant procedures Record as per Section 11.5 of the protocol
AE = adverse event; BI = Barthel Index; BDI -2 = Beck Depression Inventory 2; CT= computed tomography; ECG = electrocardiogram; FIM = Functional Independence Measure ; 
FSS =Fatigue Severity Scale ; HRU = health resource utilization; LKN = last known normal; MoCA = Montreal Cognitive Assessment; MRI = magnetic resonance imaging; 
mRS = modified Rankin Scale; NIHSS = National Institute of Health Stroke Scale; PD =pharmacodynamic; PK =pharmacokinetic; SAE = serious adverse event; SDMT = 
Symbol -Digits Modalities Test; SIS -16 = Stroke Impact Scale -16.
Note:  All timepoints , except “ within 1 hour after the end of the infusion”, are relative to start of st udy treatment administration.
1All Screening assessments must be performed prior to infusion.  Screening assessments that are performed as standard of care do not need to be repeated for the study, 
provided that Biogen has access to the information and da ta are recorded in subject’s case report form.  Data collected for the Screening assessments will be used for patient 
baseline analysis in this study.  The ECG and CT or MRI assessments results should already be available at Screening (as they are performe d as part of the standard of care), 
and a copy of the images and report should be filed with the subject’s study records.
2All Screening assessments must be performed prior to infusion.  The 0 Hours vital signs assessments are to be performed within 15 mi nutes prior to study treatment 
administration.  If the Screening NIHSS is performed more than 1 hour prior to study treatment administration, it must be repeated during the visit at 0 Hours before study 
treatment administration .
3Day 5 assessments are to occur on Day 5 or earlier if discharged, but must occur prior to discharge.
4The subject will be asked to complete the Day 30 andDay 90 Follow -UporEarly Termination assessments in person (see Section 7.2.3 and Section 10.2).  If the subject is 
unable to return to the study center to complete the Day 30 orDay 90 (Follow -up or Early Termination) assessments in person, safety information will be collected by 
telephone or remotely, as local regulations allow and pending medical monitor approval, and will include the collection of AEs, SAEs, FIM, mRS, BI , BDI- 2, SIS -16, EQ -5D-
3L, physical/neurological exam ination , vital signs, hematology/blood chemistry, serum biomarkers, PD sampling, PK sampling, anti -natalizumab antibodies, NIHSS, MoCA, 
SDMT, FSS, HRU, and concomitant medications.
5Medical history should include an assessment of prior substance abuse.
6Vital signs collected at each of the specified timepoints include temperature, blood pressure, pulse or heart rate, and respi ratory rate.  Vital signs col lected as part of the 
subject’s standard of care and that fall within 30 minutes of a study visit do not need to be repeated for the study, provided that Biogen has access to the information and data 
are recorded in the subject’s case report form.
7Requir ed only for women of childbearing potential.  If a serum beta human chorionic gonadotropin test was performed as part of the subject’s standard of care, the results will 
be accepted in lieu of the urine pregnancy test.
8An mRS assessment will be done on D ay 5, or earlier if discharged.
9Per instructions on the SIS -16, BDI -2, and FSS forms, the subject or proxy should provide responses as it applies to the prior 2 week period.  When completing th e SIS -16 
BDI-2, and FSS assessments during the Day 5 Visit, the subject or proxy should consider only the time period starting between the initial stroke (LKN) and the Day 5 Visit.
10The subject must be observed for 1 hour after completion of infusion.11The stroke etiology will be assessed based on the subject’s standard of care and diagnostic testing.  
This should be completed at Day 5 or earlier if discharged, but if results are incomplete, it may be completed at Day 30.
Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
5Rationale:   As natalizumab (both 300 mg and 600 mg) and placebo are given a s infusions over 2
hours, the original wording for the collection of PK/P Dsamples would not be appropriate as the 
infusion would still be ongoing.  Thus, a column heading in Table 1 was revised to ensure that 
the blood samples for PK/PD assessments, as we ll as vital sign measurements, are taken within 
1hour after the infusion has stopped.
In order to get appropriate PK/PD results, the blood samples need to be taken within 1 hour after 
the infusion has stopped.
This change also affects Section 7.1, Study Overview .
Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
6SUMMARY OF MAJOR CHANGES TO THE PROTOCOL
Changes to the protocol are presented chronologically.  New text is shown in bold type; deleted 
text is shown with a strikethrough .
No other major changes were made to the protocol.
Protocol 101SK202 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
7SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate :
The version number and date were updated throughout the protocol.
The version number and date of the superseded version of the protocol were updated.
In Table 1, the Schedule of Activities, the Section numbers cited for serious adverse 
event and adverse event reporting were changed to the correct sections.
Changed the Note to include “within 1 hour after the end of the infusion”
The first sentence of footnote 2 was moved to the beginning of footnote 1
In Figure 1, Stud y Schema, a footnote was added to state PK/PD/biomarker sample 
times are conducted within 1 hour after the end of the infusion.
Minor format changes to Section 7.1 were made to ensure proper cross -referencing.
Spelled out examination throughout text (previously  ‘exam’)
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
1Biogen MA Inc.
250 Binney Street
Cambridge, MA  02142
United States
Biogen Idec Research Limited
Innovation House
70 Norden Road
Maidenhead Berkshire
SL6 4AY
United Kingdom
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol
 101SK202/[STUDY_ID_REMOVED]
A Multicenter, Double -Blind, Placebo- Controlled, Randomized, Parallel- Group, Dose -Ranging 
Study
 to Evaluate the Safety and E fficacy  of Intravenous Natalizumab (BG00002) in Acute 
Ischemic Stroke
Version 2.0
Date:  
15 December 2016
EUDRA CT Number:  2015- 004783- 11
Version 2.0 of the protocol has be en prepared for this amendment, which supersedes Version  1.0.

Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
2PRIMARY REASON FOR AMENDMENT
The primary  reason for this amendment to Protocol 101SK202 is to remove unnecessary  study  
procedures (i.e., 0 hour blood draw and the Functional I ndependence Measure at Day 5)and to 
add a n expanded treatment window (>9 to ≤ 24 hours) in which subjects would be eligible for 
inclusion in the trial.
New text is shown in bold ty pe; deleted text is shown with a strikethrough .
Section 4.2 ,Schedule of Activities
Now reads:
See pages 4and 5for updated schedule of activities.
Rationale:   To relieve the burden of too man y procedures on the subjects and the study  centers.
Section 7.1, Study  Overview
Now reads:
This is a Phase 2, multicenter, double -blind, placebo -controlled, randomized, dose -ranging, 
3-arm stud y of natalizumab administered ≤924 hours from when the subject was LKN in subjects 
with acute ischemic stroke.  T his study  will evaluate the efficacy  and safety of natalizumab over 
a 90-day period.   This study  will be conducted at approximately  67 sites in the Unites States and 
Europe .
After completing screening assessments and fulfilling the criteria for study  entry , eligible 
subjects in each of 2 treatment windows ( ≤9 hours and >9 to ≤24 hours from LKN) will be 
randomized in a 1:1:1 ratio to 1 of 3 treatment groups, each of which will receive a single dose at 
0 Hours (Day  1) according to one of the following 3 regimens:  600 mg IV natalizumab, 
300mgIV natalizumab, or placebo IV.
Rationale:  In experimental rodent models, immune cell infiltration in the brain parench yma 
following an i schemic stroke occurs predominantly  after 24 hours of lesion onset, reaching its 
peak at approximately  3 day s after the index event.  Congruentl y, blockage of maladaptive 
immune responses through immune modulatory  treatments as far as 5 days after ischemia onset 
hasbeen demonstrated to y ield significant beneficial effects in rodent models, suggesting that 
therapies targeting l ymphocy te infiltration after ischemia may  have a prolonged therapeutic 
window.
A stratified randomization process was adopted in Study  101SK201 to evaluate the potential 
time dependency  of treatment effect when administering 300 mg of natalizumab in a 9- hour 
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
3window as compared to placebo.  In this study , half of the subjects in the intent -to-treat 
population were assigned to receive st udy treatment at ≤6 hours from last known normal (LKN), 
while the other half had study  treatment administered within the >6 to ≤9 hour window.  Results 
from Study  101SK201 indicated that estimates of treatment effect favored natalizumab against 
placebo at both treatment windows, with no evidence of time dependency for the treatment 
benefit .  Likewise, the safety  profile of natalizumab treatment was comparable in the ≤6 hour 
and the >6 to ≤9 hour treatment windows, with a small decrease in the proportion of deaths (21% 
and 15%, respectivel y) and serious adverse events (47% and 45%, respectively) being reported
among subjects treated in the later treatment window.
Based on these observations, the therapeutic window for natalizumab therapy  appears to be 
greater than 9 hours.  Therefore, Study 101SK202 will further explore thetime dependency  of 
thetreatment effect of natalizumab in patients with acute ischemic stroke by  enrolling a limited 
number of subjects within the treatment window of >9 to ≤24 hours from L KN.
This change also affec ts Section 4.1, Study  Schematic; Section 5.5, Rationale for the Treatment 
Window of ≤24 Hours from L KN; Section 6.2, Secondary  Objectives and Endpoints; Section 
7.2.2, Treatment; Section 8.1, I nclusion Criteria; Section 9.2, Randomization and Registration of 
Subjects; Section 16.1.2.1, Analy sis of the Primary  Endpoint; Section 16.1.2.2, Analy sis of the 
Secondary  Endpoints; Section 16.1.2.2.1, mRS and BI at Day  90; Section 16.1.2.2.2, SIS-16 and 
MoCA at Day  90; Section 16.1.2.2.3, NIHSS at Day  90; Section 16.6 ,Sample Size 
Considerations ; and Section 20, References.
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f Biogen MAInc.
4Table 1: Schedule of Activities for Stud y 101SK202
Tests and Assessments Screening1,20 Hours
(Day 1)Within 1 Hour 
After EndStart of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination54
±5 Days
Informed consent X
Confirm eligibility X
Demographics and medical 
history65X
Physical and neurological 
examinationX X X X X
Vital signs76X X X X X X X
Height (if available) and weight X (anytime from Screening to Day 5 Visit)
Urine pregnancy test87X
Hematology and blood 
chemistryX X X X X X X
Serum biomarkers X X X X X X
PD sampling X X X X X X X
PK sampling X X X X X X X
Blood sample for 
anti-natalizumab antibodiesX X X
NIHSS X X2X X X X
mRS X98X X
BI X X X
SIS-16 X109X X
MoCA X X X
Functional I ndependence 
MeasureX X X
SDMT X X X
Fatigue Severity Scale X109X X
Beck Depression I nventory 2 X109X X
HRU questionnaire X X X
EQ-5D-3L X X X
Study treatment 
administration1110X
Stroke subtype classification1211X
SAE reporting Record as per Section 15.2 of the protocol
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f Biogen MAInc.
5Tests and Assessments Screening1,20 Hours
(Day 1)Within 1 Hour 
After EndStart of 
Infusion12 Hours
±3 Hours24 Hours
±6 Hours Day 53Day 304
±5 DaysDay 90 Follow -up4/
Early Termination54
±5 Days
AE reporting Record as per Section 15.2 of the protocol
Concomitant medications Record as per Section 11.5 of the protocol
Concomitant procedures Record as per Section 11.5 of the protocol
AE = adverse event; BI = Barthel Index; BDI -2 = Beck Depression Inventory 2; CT= computed tomography; ECG = electrocardiogram; FIM = Functional Independence Measure ; 
FSS =Fatigue Severity Scale ; HRU = health resource utilization; LKN = last known normal; MoCA = Montreal Cognitive Assessment; MRI = magnetic resonance imaging;
mRS = modified Rankin Scale; NIHSS = National Institute of Health Stroke Scale; PD = pharmacodynamic; PK =pharmacokinetic; SAE = serious adverse event; SDMT = 
Symbol -Digits Modalities Test; SIS -16 = Stroke Impact Scale -16.
Note:  All timepoints are relative to start of study treatment administration.
1Screening assessments that are performed as standard of care do not need to be repeated for the study, provided that Biogen has access to the information and data are recorded 
in subject’s case report form.  Data collected for the Screening assessments will be used for patient baseline analysis in th is study.  The ECG and CT or MRI a ssessments 
results should already be available at Screening (as they are performed as part of the standard of care), and a copy of the i mages and report should be filed with the subject’s 
study records.
2All Screening assessments must be performed prior t o infusion.  The 0 Hours vital signs assessments are to be performed within 15 minutes prior to study treatment 
administration.  If the Screening NIHSS is performed more than 1 hour prior to study treatment administration, it must be repeated during the vi sit at 0 Hours before study 
treatment administration .
3Day 5 assessments are to occur on Day 5 or earlier if discharged, but must occur prior to discharge.
4If the patient is unable to return to the study center to complete a visit in person, the Day 90 Follow -Up can be completed over the telephone or remotely, as local regulations 
allow and pending medical monitor approval.  The Day 90 Follow -Up consist sof the collection of AEs, SAEs, FIM, mRS, BI, BDI -2, SIS -16, EQ -5D-3L, 
physical/neurological exam, v ital signs, hematology/blood chemistry, serum biomarkers, PD sampling, PK sampling, anti -natalizumab antibodies, NIHSS, MoCA, SDMT, 
FSS, HRU, and concomitant medications.
54The subject will be asked to complete the Day 30 and Day 90 Follow -Up or Early Ter mination assessments in person (see Section 7.2.3 and Section 10.2 ).  If the subject does 
notis unable to return to the study center to complete the Day 30 or Day 90 (Follow -up or Early Termination )assessments in person, safety information will be collect ed by 
telephone or remotely, as local regulations allow and pending medical monitor approval, and will include the collection of AEs, SAEs, FIM, mRS, BI , BDI- 2, SIS -16, EQ -5D-
3L, physical/neurological exam, vital signs, hematology/blood chemistry, serum bi omarkers, PD sampling, PK sampling, anti -natalizumab antibodies, NIHSS, MoCA, SDMT, 
FSS, HRU, and concomitant medications.
65Medical history should include an assessment of prior substance abuse.
76Vital signs collected at each of the specified timepoints include temperature, blood pressure, pulse or heart rate, and respiratory rate.  Vital signs collected as part of the 
subject’s standard of care and that fall within 30 minutes of a study visit do not need to be repeated for the study, provided that Biogen has access to the information and data 
are recorded in the subject’s case report form.
87Required only for women of childbearing potential.  If a serum beta human chorionic gonadotropin test was performed as part o f the subject’s standard of c are, the results will 
be accepted in lieu of the urine pregnancy test.
98An mRS assessment will be done on Day 5, or earlier if discharged.
109Per instructions on the SIS -16, BDI -2, and FSS forms, the subject or proxy should provide responses as it appli es to the prior 2 week period.  When completing the SIS-16 
BDI-2, and FSS assessments during the Day 5 Visit, the subject or proxy should consider only the time period starting between the initial stroke (LKN) and the Day 5 Visit.
1110The subject must be observed for 1 hour after completion of infusion.
1211The stroke etiology will be assessed based on the subject’s standard of care and diagnostic testing.  This should be complete d at Day 5 or earlier if discharged, but if results are 
incomplete, it may b e completed at Day 30.
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
6SUMMARY OF MAJOR CHANGES TO THE PROTOCOL
Changes to the protocol are presented chronologically.  New text is shown in bold type; deleted 
text is shown with a strikethrough .
Section 3, Sy nopsis
The Sy nopsis was revised to reflect changes made throughout the protocol.
Section 8.1, I nclusion Criteria
Change:   A National Institute of Health Stroke Scale (NIHSS) Screening score for eligibility  
was added for the > 9 to ≤24 hour treatment window , and NIHSS eligibility  is to b e confirmed 
within 60 minutes prior to randomization.
Now reads:
4.  Score of 5 to 23 points, inclusive, on the NIHSS at Screening for subjects initiating 
treatment ≤9 hours from LKN.  Note:  NIHSS eligibility must be confirmed within 
60minutes prior to randomization.
5.  Score of 5 to 15 points, inclusive, on the NIHSS at Screening for subjects initiating 
treatment >9 to ≤24 hours from LKN.   Note:  NIHSS eligibility must be confirmed within 
60minutes prior to randomization.
Rationale :The maximum NIHSS Screening score for subjects initiating treatment in the >9 to 
≤24 hour window was set at 15 points because prognosis associated with higher NIHSS scores is 
worsened when present at later time points.   The timeframe for confirming NIHSS eligibility  was 
clarified to occur 60 minutes prior to randomization .
This change also affects Section 4. 2, Schedule of Activities.
Section 8.2, Exclusion Criteria
Change s:(1) Patients with rapidly  improving or minor stroke sy mptoms or (2) with petechi al 
hemorrhages ≤1 cm are no longer excluded from the study .  (3) The statement regarding 
performing brain magnetic resonance imaging ( MRI )to assess subject eligibility  was removed.
The ty pesof exclusionary  strokes w ereclarified.   (4) The exclusion criteria regarding hepatitis 
infections and bacterial, fungal, or viral infections were simplified.
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
7Now reads :  
1.  Rapidly  improving or minor stroke sy mptoms
2.1.Lacunar or isolated brainstem or cerebellar stroke based on clinical assessment and 
availa ble acute imaging studies performed under the standard of care .  If it is unclear whether 
the subject has had a lacunar stroke based on clinical findings and head CT results, a brain MRI 
should be performed to assess eligibility , provided that all other inclusion criteria are met
3.2.Presence of acute intracranial hemorrhage on acute brain CT or MRI .  However, petechial 
hemorrhages of ≤1cm are not exclusionary.
[…]
10.9. Known history  of active viral hepatitis B or C positive test result for hepatitis C virus 
antibody  or current hepatitis B infection (defined as positive for hepatitis B surface antigen 
[HBsAg] and hepatitis B core antibod y [HBcAb]).  Subjects with immunity  to hepatitis B from 
active vaccination or previous natural infection (defined as ne gative HBsAg, positive hepatitis B 
surface antibod y immunoglobulin G, and negative HBcAb) are eligible to participate in the stud y 
(per the US Centers for Disease Control and Prevention’s interpretation of the hepatitis B 
serology  panel)
13.12.Signs and S symptoms of bacterial, fungal, or viral infection (including upper respiratory  
tract infection) within 14 days prior to randomizationactive or acute infection
Rationale :  (1) Subjects who experience rapid improvement in stroke s ymptoms may  still be 
eligible to participate in the study  based on their NIHSS score at the time of eligibility . Subjects 
with an NIHSS score of 5 or more, as specified in the inclusion criteria, would not have min or 
stroke sy mptoms .  (2) A brain MRI  is not a study  procedure and should be performed according 
tostandard of care.  C erebellarstrokes are considered exclusionary .  (3) Petechial hemorrhage is 
associated with baseline NIHSS and is commonly observed in mo derate to severe ischemic 
strokes.  Petechial hemorrhage is not associated with poor clinical outcome and is easily  
distinguishable from parenchy mal hemorrhage in imaging studies.  Results from Study  
101SK201 supported that treatment with natalizumab had no impact on the rate of hemorrhagic 
transformation .  Therefore ,small petechial hemorrhages should not be considered exclusionary  
in this study .  In addition, p etechial hemorrhages are likely to be randoml y well balanced among 
thetreatment arms because th e randomization process stratifies for stroke severit y.(4)
Laboratory testing for infections is not required as a study  procedure ,and th elevel of detail 
specified in the original exclusion criteria may be difficult to obtain from a patient’s medical 
history .  Furthermore, only  active or acute infection events that are ongoing at the time of 
eligibility  assessment should be considered exclusionary .
Section 11.5.1, Concomitant Therap y, and Section 11.5.2, Concomitant Procedures
Change:   Thromboly tic treatments/ procedures will be recorded as concomitant regardless of 
whether they  are given before or after informed consent .
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
8Section 11.5.1 n ow reads :
A concomitant therap y is any drug or substance administered between time of informed consent 
or authorization to enroll and completion of assessments at the Day  90 Follow -Up visit (as 
required b y the protocol).  All thrombolytic treatments (i.e., IV andintra-arterial rtPA )and 
mechanical thrombectomy that a subject receives are to be recorded as concomitant 
therapy regardless of whether they are given before or after the time of informed consent.
Section 11.5.2 now reads:
A concomitant procedure is any  therapeutic intervention (e.g., surgery /biopsy , phy sical therap y) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
the time the subject is enrolled in the study  and Safety  Follow -Up.  All thrombolytic treatments 
and mechanical thrombectomy that a subject receives are to be recorded as concomitant 
procedures regardless of whether they are given before or after the time of informed 
consent.
Rationale:   All thromboly tic treatments need to be recorded.
Section 15.5, Contraception Requirements
Change :  Contraception requirements were updated.
Now reads :  
For the purposes of the study , highl y effective contraception is defined as use of 1 or more of
contraception that achieves a failure rate of less than 1% when used consistently and 
correctly, and includes the following:
For females:
Established use of oral, intravaginal, or transdermal combined (estrogen and 
progestogen containing) hormonal methods of contraception associated with the 
inhibition of ovulation.
Established use of oral, injected, or implanted progestogen- only hormonal methods 
of contraception associated with the inhibition of ovulation . 
Placement of an intrauterine device or intrauterine hormone -releasing system.
Bilateral tubal occlusion
Barrier methods of contraception with use of a spermicide:  condom or occlusive cap 
(diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream suppository .  
The use of barrier contraceptives should always be supplemented with the use of a 
spermicide.
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
9Male surgical sterilization ( For female subjects participating in the study, male 
sexual partners must have undergone surgical sterilization with the appropriate 
postvasectomy  documentation of the abse nce of sperm in the ejaculate ).  (For female 
subjects participating in the study , male sexual partners must have undergone surgical 
sterilization.)
For males:
Effective male contraception includes a vasectomy with negative semen analysis at 
follow -up, or the use of condoms with spermicide .
True abstinence, when this is consistent with the preferred and usual lifest yle of the subject, can 
be considered an acceptable a highly effective method of contraception based on the evaluation 
of the Investigator who should also take into consideration th e duration of the clinical study .
Rationale:   Contraception language was updated so that all subjects are instructed to use highl y 
effective methods of contraception and so that the methods of highl y effective contraception are 
defined consistentl y with the Clinical Trial Facilitation Group’s recommendations.
Section 16.6, Sample Size Considerations
Change:   The sample size was increased.
Now reads:  A sample size of 225270 (7590 per treatment group) will provide at least 8688% 
probability  for the point estimate of the OR for the primary  comparison of natalizumab (dose 
groups combined) versus placebo on the global composite measure at Day  90 to exceed 1.3 ,in 
both treatment windows (i.e., same efficacy for subjects being treated ≤9 hours and >9 to 
≤24 hours from LKN) , assuming a true OR of 1.8 as observed in Study  101SK201.   Adopting a 
conservative assumption of a 50% reduction in treatment efficacy in the >9 to ≤24 hour
treatment wind ow when compared to the ≤9 hour treatment window, this probability will 
be at least 80%.  An OR of ≥1.3 on the global outcome measure is considered to be clinicall y 
meaningful based on the effect of tPA in the 3 -to 4.5 -hour time window.  At this sample size, 
the probability  of observing a point estimate exceeding 1.3, if the true OR is ≤1(i.e., the false 
positive rate), is less than 0.2.  I n addition, if the true OR of the higher dose versus placebo is 
3.0, as observed in the subgroup with exposure above the median in Study  101SK201, the 
probability  of observing a n OR of ≥1.3 when comparing the 600 -to 300 -mg dose is at least
7674%.  To allow for approximately  6% discontinuation before Day 90 (as observed in Study  
101SK201), 240 subjects will be randomized.
Rationale :  The sample size was increased to account for the addition of a new treatment 
window (>9 to ≤24 hours from LKN ).
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
10SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate :
The version number and date were updated throughout the protocol.
A Sponsor signature page was added.
The list of abbreviations was updated.
In Section 1, Sponsor I nformation, the information on how to contact the study ’s 
Medical Monitor for urgent medical issues was updated.  This change also affects 
Section 15.3.3, I mmediate Rep orting of Serious Adverse Events, and Section 15.4.3, 
Medical Emergency .
In Section 7.1, Study  Overview, clarification was made :the timing of post -treatment 
assessments are from the start of infusion and now reads as follows:  Post-treatment 
assessments w ill be performed at the following timepoints after the start of study  
treatment administration:  within 1 hour after the endstart of the infusion, 
12 ± 3 hours after the endstart of the infusion, 24 ± 6 hours after the end start of the 
infusion, Day 5, Day 30 (±5 day s), and the Day 90 Follow -Up visit ( ±5days).   This 
change also affects Section 4.2, Schedule of Activities.
In Section 7.1, Study Overview, the following statement from the S ynopsis was 
added:  The study will be conducted at approximately 67 sites in the United 
States and Europe.
In Section 7.2.3, Follow -Up, clarification was made that subjects are to return to the 
site only  for the Day  30 and 90 assessments and if subjects are unable to return to the 
site, these assessments can be done over t he phone.  This section now reads:  Subjects 
are to return to the study  site for a follow -up visit on Day 5,Day 30,and Day 90 
(Follow -Up Visit; the final study  visit).  If the patientsubject is unable to return to the 
study  center to complete a visit in person, the Day 5, Day 30,or the Day  90 
Follow -Up visits can be completed over the telephone or remotel y, as local 
regulations allow and pending medical monitor approval.   This change also affects 
Section 4.2, Footnote 4 of the Schedule of Activities.
In Section 8.1, Inclusion Criteria, inclusion criteria were updated to identify  the t ypes 
of daily  activities the patient was able to perform and now reads as follows:  56.  Prior 
to index stroke, patient was able to perform the following basic activities of daily  
living without assistance : dressing, eating, walking, bathing, and using the toilet .
In Section 10.2, Withdrawal of Subjects From Study , a statement was added to 
indicate that subjects who withdraw from the study will not be replaced.   It was 
clarif ied that information collected for early  termination assessments can also be 
collected b y a remote visit.
In Section 13.1, Clinical Efficacy  Assessments, the reference to premorbid mRS was 
removed since it is not being collected.
Protocol 101SK202 , Version 2.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent o f 
Biogen MAInc.
11In Section 14.2, Laborator y Safet y Assessments, the reference to anti -JCV serology  
testing was removed .  This also affects Section 19.1.4, Central Laboratories for 
Laboratory  Assessments.
In Section 16.5, Interim Analy ses, it was clarified that an interim anal ysis may be 
performed after 50% of the study  population has completed the Day  30 assessment.
Typographical errors and formatting were corrected.